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ABSTRACT 
 
Studies on the development of drug resistance in several cancer types, 
including acute myeloid leukaemia (AML), have implicated the PI3-kinase 
pathway.  This pathway phosphorylates Akt resulting in the activation of 
proteins involved in cell survival.  The aim of this study is to determine the 
role that Akt plays in survival and the relationship between Akt, IKK and 
IκB in HL-60 cells.  This study demonstrated that etoposide caused 
apoptosis in HL-60 cells, which was slightly increased when the PI3-
kinase pathway was inhibited by LY294002.  Stimulation with PDGF 
resulted in cell proliferation and increased Akt, IKK and IκB 
phosphorylation.  Although pre-treatment with LY294002 decreased the 
amount of Phospho-Akt, phosphorylation of IKK and IκB still occurred.  
Therefore additional pathways must be involved in IκB regulation in HL-60 
cells.  Akt mRNA transcription was decreased when the cells were pre-
treated with LY294002 and either PDGF or etoposide.  In conclusion, the 
PI3-kinase pathway plays a minor role in the survival of HL-60 cells and 
Akt substrates other than IKK are mediating this survival.   
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CHAPTER 1 
 
INTRODUCTION 
 
Cancer is a cell growth disorder, characterised by an autonomous 
proliferation of genetically dysfunctional cells (Alberts et al, 1994; Raven & 
Johnson, 1996).  If the cells continue to replicate in an uncontrolled 
manner, they lead to a cluster of cells known as a tumour or a neoplasm.  
A tumour is considered to be non-cancerous or benign if the neoplastic 
cells remain clustered together, and the mass can generally be removed 
completely with surgery.  Cancerous or malignant tumour cells are able to 
invade the surrounding tissue, as well as break away from the tumour.  
These enter the blood or lymph vessels and form secondary tumours 
known as metastases in other parts of the body (Alberts et al, 1994). 
 
Cancers are generally classified according to the tissue and cell type from 
which they develop.  Carcinomas develop from epithelial cells, whereas 
cancers of the connective tissue or muscle cells are referred to as 
sarcomas.  Other cancers arising from haemopoietic cells, known as 
leukaemias, and nervous tissue do not fall into these categories (Alberts 
et al, 1994). 
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Many signalling pathways exist in the cell, and it has been shown that 
cancer results from a stepwise accumulation of mutations in the pathways 
affecting growth control, differentiation and cell survival.   
 
A delicate balance exists between the mechanisms that stimulate cell 
proliferation and programmed cell death.  The most commonly described 
signalling pathways include the Ras/MAPK (Mitogen activated protein 
kinase) pathway which drives uncontrolled proliferation, the 
retinoblastoma (Rb) pathway that alters the control of the cell cycle, and 
apoptosis/cell survival that is regulated by the p53 and PI3-kinase/Akt 
pathways.  Akt has also been implicated in ‘anoikis’, a process that 
prevents normal cells from detaching from the extracellular matrix (ECM).  
It is thought that an alteration in the PI3-kinase/Akt pathway allows 
cancerous cells to metastasise or drug resistance to develop (Masure et 
al, 1999).   
 
The remainder of the introduction will be focused on the PI3-kinase/Akt 
and IKK/IκB pathways, and their roles in the prevention of apoptosis with 
particular interest in leukaemia.   
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1.1 PHOSPHOINOSITIDE 3-KINASE PATHWAY 
 
1.1.1 STRUCTURE OF PI3-KINASE 
 
Courtneidge and Heber first characterised the PI3-kinase enzyme as an 
85 kDa phosphoprotein in 1987 (Domin & Waterfield, 1997).  PI3-kinase 
activity was found to be physically and functionally associated with the 
transforming activity of viral oncogenes such as SRC tyrosine kinase and 
polyomavirus middle antigen (Vivanco & Sawyers, 2002).  Subsequent 
cloning and purification of the enzyme revealed that PI3-kinase is a 
heterodimeric complex consisting of an 85 kDa adaptor (p85) and a 110 
kDa catalytic subunit (p110) (Domin & Waterfield, 1997).  The p85 
regulatory subunit is directly associated with many active tyrosine kinases 
through the physical interaction of its SH2 domain with phosphotyrosine 
residues.  In some cases, the interaction of p85 and the receptor tyrosine 
kinases is indirect, occurring through intermediate phosphoproteins, such 
as insulin receptor substrates IRS1 and IRS2 (Vivanco & Sawyers, 2002).  
Over the following years numerous PI3-kinase catalytic and regulatory 
subunits have been described resulting in a classification of the enzyme 
family according to their structure and probable mechanism of regulation.  
Seven forms of the catalytic subunit and five forms of associated binding 
partner/adaptor subunit have been identified in mammals, and have been 
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divided into three main classes; class I, II and III (Domin & Waterfield, 
1997; Astoul et al, 2001; Vivanco & Sawyers, 2002).    
 
1.1.2 REGULATION OF PI3-KINASE ACTIVITY 
 
Most of the understanding about the PI3-kinase family has been gained 
from the study of class I molecules, which consist of a p85 regulatory 
domain and a p110 catalytic domain.  The class I PI3-kinases appear to 
play a role in almost every receptor mediated signalling event, and are 
tightly regulated in normal cells by various mechanisms.  A pre-formed 
inactive p85-p110 complex is situated in the cytoplasm of resting cells 
awaiting activation.  When ligand binding to a receptor tyrosine kinase 
occurs, it results in the activation of kinase activity and 
transphosphorylation of the receptor tyrosine kinase cytoplasmic tail.  The 
p85-p110 complex is recruited to the receptor by the phosphorylation of 
tyrosine residues presented within a pTyr-X-X-Met consensus sequence, 
which acts as docking sites for the class IA adaptor subunit SH2 domains.  
In some cases the interaction may be with the IRS1/IRS2 signalling 
intermediates.  Lipid kinase activity is activated by phosphopeptide binding 
to the p85 SH2 domains and the catalytic subunit is brought into close 
proximity with its lipid substrate by translocation to the plasma membrane.  
This also results in an increase in PI3-kinase activity by facilitating an 
interaction with GTP bound ras (Fig. 1.1) (Domin & Waterfield, 1997; Tu et 
al, 2000; Vivanco & Sawyers, 2002). 
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Figure 1.1 Three possible activation pathways of PI3-kinase (Adapted 
from Vivanco & Sawyers, 2002). 
 
The generation of PtdIns(3,4,5)P3, a second messenger, from 
PtdIns(4,5)P2 is the primary repercussion of PI3-kinase activation.  Due to 
the effects of strict PI3-kinase regulation and the action of several 
PtdIns(3,4,5)P3 phosphatases (PTEN, SHIP1 and SHIP2) (Fig. 1.2), 
PtdIns(3,4,5)P3 levels are barely detectable in unstimulated mammalian 
cells.  PTEN functions primarily as a PtdIns(3,4,5)P3 lipid phosphatase 
that converts PtdIns(3,4,5)P3 to PtdIns(4,5)P2, but it is thought to also 
have activity against protein substrates (Ramaswamy et al, 1999; 
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Burgering & Kops, 2002; Vivanco & Sawyers, 2002).  SHIP phosphatases 
also act on PtdIns(3,4,5)P3, but remove the phosphate from the 5’ position 
resulting in the production of PtdIns(3,4)P2 (Fig. 1.2).  PtdIns(3,4)P2, like 
PtdIns(3,4,5)P3 act as secondary messengers and recruit proteins, such 
as Akt, which contain a PH-domain.  Both PTEN and SHIP reduce the 
level of PtdIns(3,4,5)P3, however PTEN appears to play the major role in 
the control of the mitogenic effects of phosphoinositides.  This has been 
shown as knockout mutations in Pten give a stronger cancer phenotype in 
mice than Ship1 (Vivanco & Sawyers, 2002). 
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Figure 1.2 Phosphoinositol 3-kinase (PI3-kinase) phosphorylation of 
PtdIns(4,5)P2 at the D3 position giving rise to the second 
messenger PtdIns(3,4,5)P3.  PtdIns(4,5)P2 is regenerated by 
the dephosphorylation of PtdIns(3,4,5)P3 by PTEN.  
Dephosphorylation of PtdIns(3,4,5)P3 by SHIP1/2 
occasionally occurs at the D5 position forming PtdIns(4,5)P2.  
(Adapted from Vivanco & Sawyers, 2002). 
           
1.1.4 DOWNSTREAM TARGETS OF PI3-KINASE   
  
The PI3-kinase pathway appears to have several downstream targets as 
the phospholipid products of PI3-kinase bind to the pleckstrin homology 
(PH) domains of proteins.  This either modifies their activity or causes 
them to be translocated to the membrane (Domin & Waterfield, 1997). 
.   
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Evidence has shown that even though activation of p70S6 kinase is a 
result of Ser/Thr protein kinase independent of the Raf/MAPK pathway, it 
is an important downstream target of PI3-kinase.  p70S6 kinase plays a 
key role in G1 to S phase transition in the cell cycle, by phosphorylating 
the 40S ribosomal protein S6 in response to mitogenic stimuli (Domin & 
Waterfield, 1997). 
 
Rac, the ras related GTP binding protein is also thought to be a 
downstream target of PI3-kinase.  The protein is said to activate the 
JNK/stress activated protein kinase, which phosphorylates c-jun (Domin & 
Waterfield, 1997). 
 
Activation of calcium-independent isoforms of protein kinase C and protein 
kinase C related kinases appear to be the result of binding to 3’ 
phosphoinositides.  This has been found in vitro and is thought to be the 
case in whole cells, but the specificity of this activation is a contentious 
issue (Domin & Waterfield, 1997). 
 
PDK1 or 3-phosphoinositide-dependent protein kinase is activated by PI3-
kinases, PtdIns(3,4,5)P3 and PtdIns(3,4)P2.  Due to the presence of a PH 
domain, it is thought that PI3-kinase activity causes PDK1 to be 
translocated to the membrane.   PDK1 also contains a catalytic domain 
with homology to cAMP-dependent protein kinase (PKA) Akt and protein 
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kinase C (PKC) subfamily (Brazil & Hemmings, 2001; Burgering & Kops, 
2002).   
 
Akt, also called protein kinase B, is a Ser/Thr kinase and is the cellular 
homologue of the retroviral oncogene v-akt.   This kinase will be discussed 
in more detail below. 
 
 
1.2 AKT/PROTEIN KINASE B 
 
Staal and co-workers first described Akt/Protein kinase B in 1977. They 
discovered a transforming murine leukaemia virus (AKT8) which had a 
high incidence of spontaneous lymphoma in the mink epithelial cell line 
CCL-64.  The inability of AKT8 to induce focus formation in other cell lines 
such as NIH3T3 fibroblasts suggested that the virus contained an 
undescribed oncogene.  The isolation of the retrovirus from AKT8 infected 
mink lung epithelial cells showed that AKT8 contained a cell-derived 
oncogenic sequence called Akt.  The hypothesis that this gene played a 
role in the pathogenesis of human malignancy was strongly supported by 
the identification of two human homologues, Akt1 and Akt2, and the 
amplification of a fragment of the Akt1 gene in gastric adenocarcinoma 
cells.  Further research showed evidence of the oncogenic potential of Akt 
when they demonstrated that the AKT8 virus induced tumour formation, 
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specifically thymic lymphoma, in nude mice (Staal, 1987; Bellacosa et al, 
1991; Brazil & Hemmings, 2001).  
 
No further research on the properties of Akt was reported until 1991, when 
three independent research teams identified genes corresponding to 
PKB/Akt.  The first was from Jones and co-workers identifying a gene 
encoding a serine/threonine protein kinase, named Rac (related to the A 
and C kinases) and was subsequently renamed PKBα/Akt1. Akt was 
shown to have in vitro kinase activity with histone H1 as a substrate.   
Similar work by Bellacosa and colleagues later that year described the 
cloning of v-Akt by fusing the cDNA of the viral GAG protein and the α-
isoform of Akt.  These results showed that a strong similarity exists 
between the v-Akt and protein kinase C sequence and when run on a 
SDS-PAGE there was a retarded migration suggesting phosphorylation of 
the protein (Bellacosa et al, 1991; Brazil & Hemmings, 2001).  Lastly a 
PCR screening approach used by Coffer and Woodget demonstrated the 
significant homology of PKB to protein kinase C and protein kinase A.  Akt 
contains a centrally located catalytic domain, which shows a high degree 
of homology to those of both protein kinase C and protein kinase A, 75% 
and 65% respectively (Andjelkovic et al, 1996; Brazil & Hemmings, 2001).  
The combination of these results and the discovery of the second form of 
Akt, PKBβ/Akt2, identified Akt as a widely expressed phospho-protein 
kinase (Okano et al, 2000; Brazil & Hemmings, 2001).  
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Staal and co-workers detected amplification of Akt1 in gastric 
adenocarcinoma, resulting in further investigation of the role of the Akt 
genes in human cancers.  Similarly Cheng and colleagues demonstrated 
the amplification of the Akt2 gene in two ovarian carcinoma cell lines.  
This led to the conclusion that amplification of Akt genes may contribute to 
the pathogenesis of certain cancers and opened the door for the 
investigation of the role of Akt in many cellular processes including 
glucose metabolism, transcription, apoptosis, proliferation, migration, 
angiogenesis and cell growth (Staal, 1987; Brazil & Hemmings, 2001). 
 
1.2.1 THE STRUCTURE OF AKT 
 
The analysis of the amino acid sequence of Akt revealed an N-terminal 
region with homology to a modular domain called the pleckstrin homology 
(PH) domain.  The PH domain, containing ∼100 amino acids, has been 
identified in more than 90 signalling and cytoskeletal molecules including 
Akt, RasGAP, mSOS and β-spectrin, many of which are associated with 
membranes (Andjelkovic et al, 1996; Stokoe, et al, 1997; Brazil & 
Hemmings, 2001).  This PH domain was thought to mediate the 
interaction of Akt with other proteins.  Fesik and co-workers demonstrated 
that PtdIns(3,4,5)P2 could bind to the PH domain of proteins, leading to 
the hypothesis that phospholipids interacted with the PH domain of Akt 
(Stokoe et al, 1997; Brazil & Hemmings, 2001).    
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In 1995, experiments on the Akt homologue in Drosophila melanogater, 
DRAC-PK, revealed that the protein has a 75% homology to the human 
isoforms, and is ubiquitously expressed throughout the Drosophila life 
cycle.  Akt activity in Drosophila appears to be developmentally regulated 
as it is ∼8 fold higher in adult flies than in early embryos (Andjelkovic et al, 
1996; Brazil & Hemmings, 2001).  It was also shown that the PH domain 
of Akt mediates protein-protein interactions.  The identification of a 
relationship between PI3-kinase activity and Akt activation revealed that 
the membrane phospholipids generated by PI3-kinase were essential for 
the activation of Akt (Brazil & Hemmings, 2001). 
 
Three main isoforms of Akt have now been identified in mammalian cells: 
PKBα/Akt1, PKBβ/Akt2 and PKBγ/Akt3.  The amino acid sequences for 
Akt2 and Akt3 have 81% and 83% homology with Akt1 respectively. Akt 
has two phosphorylation sites required for full activation, on Akt1 they are 
at Thr308 and Ser473, but on Akt2 and Akt3 they are at Thr309/305 and 
Ser474/472 respectively.  PKBα/Akt1 has been found to be overexpressed in 
the breast cancer epithelial cell line (MCF-7), PKBβ/Akt2 is overexpressed 
in a number of ovarian and pancreatic cancers, with both appearing to be 
ubiquitously expressed.  Akt3 is expressed predominantly in the brain, 
heart and kidney (Alessi et al, 1996; Masure et al; 1999; Okano et al, 
2000).   
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1.2.2 AKT REGULATION 
 
Both the PH domain and the phosphorylation of Akt appeared to regulate 
Akt activity.  This concept was supported by data showing that Akt was 
activated by both serum stimulation and protein phosphatase inhibitors 
(such as pervanadate). The kinase activity of Akt was inhibited by 
incubating cells with protein phosphatase 2A (PP2A), suggesting that Akt 
activity is controlled by reversible phosphorylation on both serine and 
threonine residues (Andjelkovic et al, 1996; Brazil & Hemmings, 2001).  
Chaperone protein heat-shock protein 90 (HSP90) protects Akt from 
dephosphorylation by PP2A hence preventing its inactivation.  The 
recently identified carboxy-terminal modulator protein (CTMP) has also 
been shown to bind to Akt, inactivating it and preventing phosphorylation 
and downstream signalling (Vivanco & Sawyers, 2002).   Alessi, 
Andjelkovic and colleagues demonstrated the exact mechanism of this 
phospho-regulation by treating cells with insulin or insulin-like growth 
factor (IGF-1), causing Akt to be activated by phosphorylation on residues 
Thr308 and Ser473.  The addition of either of the PI3-kinase pathway 
inhibitors, wortmannin or LY294002, or the mutation of these amino acid 
residues caused a decrease in Akt activity.  A model of Akt activation was 
becoming apparent.  Full activation of Akt appeared to require the 
recruitment of Akt to the plasma membrane.  The PH domain binds to 
PtdIns(3,4,5)P3 and phosphorylation occurs on Thr308 in the T-loop of the 
catalytic domain and Ser473 in the C-terminus of the α isoform by one or 
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more upstream kinases (Andjelkovic et al, 1998; Brazil & Hemmings, 
2001). 
 
 An intensive search for the upstream kinases responsible for 
phosphorylating Akt was sparked by the discovery that phosphorylation on 
the serine and threonine residues was essential for the regulation of Akt.  
Within a year a kinase was purified from both rabbit skeletal muscle and 
rat brain that phosphorylated Akt on Thr308 activating the kinase.  
Consistent with previous work, it was shown that insulin stimulated Thr308 
and Ser473 phosphorylation was abolished when PI3-kinase was inhibited.  
It was also demonstrated that this protein was activated by the products of 
PI3-kinase, PtdIns(3,4,5)P3 and PtdIns(3,4)P2, leading to it being named 
3-phosphoinositide-dependent protein kinase or PDK1.  The cloning of 
PDK1 revealed a C-terminal PH domain thought to be involved in lipid 
binding and a catalytic domain with homology to cAMP-dependent protein 
kinase (PKA) Akt and protein kinase C (PKC) subfamily.  The PH domain 
suggests that PI3-kinase activity causes PDK1 to be translocated to the 
membrane, however the catalytic activity of PDK1 appears to be 
constitutive and remains largely unchanged after PI3-kinase activation.  It 
is therefore thought that PI3-kinase activity is not only responsible for the 
membrane localisation of PDK1, but regulates both the localisation and 
activation of Akt (Stephens et al, 1998; Brazil & Hemmings, 2001; 
Burgering & Kops, 2002).  The phosphorylation of Akt by PDK1 appears to 
be conformationally regulated, as the PH domain of Akt masks its 
  15 
activation site.  Therefore Akt must bind to PtdIns(3,4,5)P3 or 
PtdIns(3,4)P2, causing the auto-inhibition to be relieved and allowing 
PDK1 to access Thr308 on the activation loop (Toker & Newton, 2000). 
 
The kinase responsible for the phosphorylation of the C-terminal 
hydrophobic Ser473 residue remains elusive.  A number of possibilities 
have been postulated, these include MAPKAP kinase 2, Akt, PDK1, ILK, 
and PRK2 (Andjelkovic et al, 1998; Tu et al, 2000; Brazil & Hemmings, 
2001).  Recent reports have provided conflicting views on the control of 
phosphorylation on this site.  The regulation of the Ser473 has been shown 
to be both mitogen- and PI3-kinase-dependent, leading to the proposal 
that the upstream kinase is also in the PI3-kinase pathway but distinctly 
different from PDK1.  The kinase was therefore provisionally named 
PDK2.  ILK has been shown to increase Ser473 phosphorylation in 
transfected cells, however the mechanism is indirect suggesting that ILK is 
not the mysterious PDK2 (Toker & Newton, 2000).   
 
1.2.4 DOWNSTREAM TARGETS OF AKT 
 
Glycogen synthase kinase-3 (GSK-3) was the first downstream substrate 
of Akt to be identified. Akt is stimulated and GSK-3 is inhibited when cells 
are treated with insulin.  The inhibition of GSK-3 occurs when Akt 
phosphorylates Ser21 in GSK-3α and Ser9 in GSK-3β.  It was noted that 
the addition of a PI3-kinase inhibitor prevented the activation of Akt and 
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the inhibition of GSK-3.  These findings suggested that the Akt pathway 
may play a role in the control of physiological processes such as glycogen 
and protein synthesis (Alessi et al, 1996; Brazil & Hemmings, 2001) (Fig. 
1.3). 
 
Further experimentation with cerebellar granule neurons showed that the 
removal of serum or growth factors such as IGF-1 caused apoptosis.  
Evidence provided by Yao and Cooper showed that growth factor 
mediated cell survival required a PI3-kinase signal that was independent 
of p70S6 kinase.  Dudek and co-workers substantiated this by 
demonstrating that cerebellar granule cell survival mediated by IGF-1 was 
completely dependent on PI3-kinase activity and involved Akt with no 
p70S6 kinase activity.  The expression of wild-type Akt enhanced the 
survival of neurons in the absence of growth factors, however neurons 
with dominant negative mutants of Akt appeared to have increased 
apoptosis in the presence of serum.  These results pointed out a pivotal 
role that Akt plays in the neuronal survival pathway, suggesting that Akt 
may influence pathological conditions of the brain including 
hypoxic/ischaemic-induced injury and neurodegenerative disorders (Brazil 
& Hemmings, 2001) (Fig. 1.3).  
 
The possibility that Akt had an anti-apoptotic role led to the search for 
downstream targets involved in cell survival.  The first downstream target 
identified was BAD, a pro-apoptotic factor.  When phosphorylated its pro-
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apoptotic function in haematopoietic cells, in response to ligands such as 
interleukin-3, is inhibited.  It was also observed that Akt translocated to the 
nucleus in growth factor stimulated cells indicating that suppression and/or 
upregulation of gene expression could be another anti-apoptotic 
mechanism controlled by the kinase. Other downstream targets involved 
in cell survival include mTOR which is responsible for protein translation 
(Fig. 1.3).  Pro-apoptotic factors which are inhibited by Akt 
phosphorylation include ASK and caspase-9 (Brunet et al, 1999; Borgatti 
et al, 2000; Jones et al, 2000; Madge & Pober, 2000; Tang et al, 2000; 
Zhou et al, 2000; Brazil & Hemmings, 2001; Tang et al, 2001; Burgering & 
Kops, 2002; Shin et al, 2002; Steelman et al, 2004) (Fig. 1.3).  
 
Akt was found to phosphorylate and inactivate the newly discovered 
human homologues of the Caenorhabditis elegans gene encoding Daf-16 
(FKHRL1, FKHR and AFX) otherwise known as the Forkhead family of 
transcription factors. It was observed that stimulation by growth factors 
caused Akt dependent phosphorylation and inhibition of FKHRL1 function.  
The transcription of death genes such as Fas ligand gene was 
suppressed and cell survival was promoted (Brunet et al, 1999; Brazil & 
Hemmings, 2001).    The activation of IKKα resulting in the degradation of 
IκB and stimulation of NF-κB has also been linked to Akt.  Recently Akt 
has been implicated in the inhibition of apoptosis in cells treated with a 
number of agents and treatments including Fas ligation, UV radiation and 
etoposide (Brunet et al, 1999; Borgatti et al, 2000; Jones et al, 2000; 
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Madge & Pober, 2000; Tang et al, 2000; Zhou et al, 2000; Brazil & 
Hemmings, 2001; Tang et al, 2001; Burgering & Kops, 2002; Steelman et 
al, 2004) (Fig. 1.3).   
 
The search for more Akt downstream targets is continuing, a recent 
publication described the use of a peptide library to find Akt substrates 
and defined the optimal substrate sequence (Table 1.1).  Sufficient 
phosphorylation occurs when the sequence motif is Arg-Xaa-Arg-Yaa-
Zaa-Ser/Thr-Hyd, where Xaa is any amino acid, Yaa and Zaa are small 
residues except glycine, and Hyd is a bulky hydrophobic residue (Phe, 
Leu) (Alessi et al, 1996).  This consensus peptide phosphorylation 
sequence for Akt has been derived from small peptides with relatively low 
affinities, and may not represent the in vivo situation completely.  It 
appears that Akt plays a major role in cell signalling as the diverse list of 
substrates (Table 1.1) is constantly increasing.  These substrates are not 
only involved in apoptosis, but also in metabolism, cytoskeleton regulation 
and various other cellular processes (Brazil & Hemmings, 2001). 
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Figure 1.3 The process of Akt phosphorylation, showing the subsequent 
activation and inhibition of several downstream targets, 
resulting in cellular growth, survival and growth.  The black 
arrows indicate the targets that are activated, whereas the 
red arrows indicate targets that are inhibited.  (Adapted from 
Vivanco & Sawyers, 2002). 
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Table 1.1 The current list of published Akt substrates.  The amino acid 
phosphorylated by Akt is in bold (Brazil & Hemmings, 2001).  
Protein Akt Phosphorylation 
Sites 
Species Effect of Phosphorylation 
BAD 107RSRHSSY113 Human Blocks BAD-induced apoptosis 
C-Raf 130RGRSRSA137 Human Inhibits C-Raf activity 
B-Raf 254RQRSTST260 Human Inhibits B-Raf activity 
 423RERKSSS429   
BCRA-1 504KKRRPTS510 Human Interferes with nuclear localization of BCRA-1 
CREB 128LSRRPSY134 Human Increased association with CBP and p130 
eNOS 1174RIRTQSFSL1181 Human Activates eNOS and leads to NO production 
FKHRL-1 248RRRAVSM254 Human Inhibits transcriptional activity of FKHRL1 
GSK-3α 16RARTSSF22 Human Inactivates GSK-3 activity 
GSK-3β 4RPRTSSF10 Human Inactivates GSK-3 activity 
IκB kinase-α 18RERLGTG24 Human Activates transcriptional activity of NF-κB 
IRS-1 297RSRTESI303 Murine Protects IRS-1 from action of PYPase 
mTOR 2443RTRTDSY2449 Murine Activates mTOR activity 
PDE-3B 268RPRRRSS274 Murine Inactivates PDE-38 
PFK-2 460RMRRNSF467 Bovine Activates PFK-2 
 478RPRNTSV484   
Rac1 66RIRPLSY72 Human Inhibits Rac1-GTP binding 
hTERT 819RIRGKSY825 Human Enhances telomerase activity 
p21CIP1 139RKRRQTS146 Human Causes cytoplasmic localization of p21CIP1 
Nur77 345RGRLPSK351 Human Inhibits transcriptional activity of Nur77 
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1.3 THE IKK PATHWAY AND NF-κB REGULATION 
 
Stimulation of the IKK pathway occurs in response to many different 
stimuli, including cytokines, growth factors, bacterial products, viral 
infection, physiological, physical and oxidative stress, receptor ligands and 
some pharmaceutical drugs and chemicals.  Activation of IKK causes IκB 
to be ubiquitinated and degraded, releasing the nuclear transcription 
factor NF-κB and allowing it to move into the nucleus (Beraud et al, 1999; 
Delhase et al, 2000; Perkins, 2000).     
 
1.3.1 IKK PROTEIN COMPLEX 
 
The IKK protein complex was isolated as a >700 kDa complex consisting 
of three proteins, IκB kinase (IKK) α, β and γ.  IKKα (IKK1) and IKKβ 
(IKK2) are catalytic subunits whereas IKKγ/NEMO (NF-κB essential 
modulator) plays a regulatory role, and is required for IKK activation by 
upstream pathways (Perkins, 2000; Madrid et al, 2001). IKK proteins are 
Ser/Thr kinases characterised by a Leucine zipper and a helix-loop-helix 
protein interaction motif.  The Leucine zippers of IKKα and β allow the 
proteins to heterodimerize, a requirement for kinase activity (Beraud et al, 
1999). Another high molecular weight IKK complex was recently 
discovered, adding to the complexity of the pathway.  This complex 
contains IKKε, which is homologous to, but does not associate with IKKα 
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and IKKβ.  The IKKε complex appears to activate NF-κB by phorbal esters 
and cross-linking, not by TNF-α or ILK-1 (Perkins, 2000).   
 
Kinases responsible for the phosphorylation at Thr23 and activation of IKK 
complexes include members of the mitogen-activated protein kinase 
kinase (MAPKK) family, such as NF-κB-inducing kinase (NIK) and 
mitogen-activated protein kinase/ERK kinase kinase (MEKK) 1, 2 and 3.  
Others include members of the atypical protein kinase C family, Akt/PKB, 
and two IKKα and IKKβ related proteins, IKKi and NF-κB activating kinase 
(NAK).  The exact contribution of each pathway is still unclear and varies 
with different experimental conditions (Perkins, 2000). 
 
1.3.2 THE IκB PROTEIN FAMILY 
 
Another multigene family was discovered when the IκB gene was cloned.  
This family including IκBβ, IκBε and Bcl3, is structurally characterised by 5 
to 7 ankyrin-repeat motifs.  These motifs mediate the interaction with the 
Rel homology domain of NF-κB (Beraud et al, 1999; Perkins, 2000).  The 
C-termini of p100 and p105 contain similar repeats and can function as 
IκB-like proteins, retaining NF-κB complexes in the cytoplasm prior to 
proteolytic cleavage (Shah et al, 1999; Hsu et al, 2000; Perkins, 2000; 
Schmitz et al, 2001). IκB proteins contain two conserved Ser residues, 
Ser32 and Ser36 on IκBα, Ser19 and Ser23 on IκBβ, Ser18 and Ser22 on IκBε, 
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within their N-terminal domain (Beraud et al, 1999; Perkins, 2000).  Once 
the Ser32 and Ser36 residues on IκBα are phosphorylated, IκB is 
ubiquitinated and degraded by the 26S proteosome (Beraud et al, 1999; 
Romashkova et al, 1999; Delhase et al, 2000; Perkins, 2000; Pomerantz 
& Baltimore, 2000; Schmitz et al, 2001). 
 
1.3.3 NF-κB 
 
NF-κB was first discovered as a nuclear transcription factor in mature B 
cells that bound to an element in the kappa immunoglobulin light chain 
enhancer, hence its name.  It was found that NF-κB was a complex 
consisting of two subunits with molecular weights of 50 kDa (p50) and 65 
kDa (p65).  This complex is found in an inactive cytoplasmic form bound 
to the inhibitor protein IκB in most cell types.  Treatment of cells with 
inflammatory cytokines, TNF-α and IL-1, released NF-κB from IκB 
allowing its nuclear translocation and confirming NF-κB’s involvement in 
the immune response.  Other NF-κB target genes were identified, 
including cytokines, chemokines, cytokine- and immuno-receptors, 
adhesion molecules, acute-phase proteins, stress-responsive genes and 
HIV-1 (Perkins, 2000).  The isolation of the p50 gene revealed that it 
encoded for a 105 kDa protein that required proteolytic cleavage to 
generate p50.  It was found that the DNA-binding and dimerization domain 
of p50 was significantly homologous to the viral oncoprotein v-Rel, its 
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cellular counterpart c-Rel and Dorsal (the Drosophila melanogater 
developmental protein) (Perkins, 2000; Schmitz et al, 2001).  Shortly 
afterwards p65 cDNA was isolated, confirming this relationship.  A 
multigene NF-κB family was established by the discovery of two other 
highly homologous proteins, p100 (p52) and Rel-B.  The members of this 
family all contain a ∼300 amino acid N-terminal DNA binding and 
dimerization domain.  Several of these proteins, c-Rel, RelB and p65 
(RelA) contain a nonhomologous transactivation domain at their C-termini, 
and do not require proteolytic cleavage to generate their active forms 
(Beraud et al, 1999; Shah et al, 1999; Perkins, 2000; Schmitz et al, 2001).  
p52 (NF-κB2) is similar to p100/50 (NF-κB1) as it is generated by the 
proteolytic cleavage of p100.  The most commonly observed form of NF-
κB is a p50-p65 heterodimer (Shah et al, 1999; Perkins, 2000; Schmitz et 
al, 2001).   
 
1.3.4 AKT AND THE IKK PATHWAY 
 
NF-κB appears to be stimulated rapidly in response to many stimuli, 
including cytokines, growth factors, bacterial products, viral infection, 
physiological, physical and oxidative stress, receptor ligands and some 
pharmaceutical drugs and chemicals (Beraud et al, 1999; Delhase et al, 
2000; Perkins, 2000).  Several pathways are activated by these stimuli 
and result in the phosphorylation of IκB. Ozes and colleagues 
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demonstrated that Akt was required for NF-κB activation by TNF-α in 293, 
HeLa and ME-180 cells (Ozes et al, 1999; Perkins, 2000).  Zhou and 
associates found evidence that Akt activity was essential for the 
stimulation of both IKKα and β, for IκB phosphorylation and NF-κB 
activation in several breast cancer cell lines (Zhou et al, 2000). 
Furthermore in primary rat and human fibroblasts it was shown that NF-κB 
activation by PDGF and not TNF-α or phorbol esters, required Akt 
(Romashkova et al, 1999; Perkins, 2000).  In MCF-7 breast carcinoma 
cells it was found that Akt signalling activated NF-κB in both a TNF-α-
dependent and –independent manner (Burow et al, 2000).  Contrasting 
evidence by Kane and co-workers demonstrated that Akt did not activate 
NF-κB in Jurkat cells, but along with phorbal esters resulted in an 
enhanced degradation of IκB (Kane et al, 1999; Perkins, 2000).  Two 
groups, Sizemore and colleagues and Madrid and co-workers, 
contradicted these findings by examining the IL-1 or oncogenic H-Ras-
mediated activation of NF-κB in HepG2 and NIH 3T3 cells respectively.  
They reported that Akt could activate NF-κB transactivation, however it 
was not at the IκB level of phosphorylation and NF-κB nuclear 
translocation.  They found that Akt stimulated the p65 (RelA) 
transactivation domain to induce transcription (Sizemore et al, 1999; 
Delhase et al, 2000; Madrid et al, 2000; Perkins, 2000).  An overlapping 
role of the IKK complexes could explain these discrepancies, as both 
dominant-negative IKKε and IKKα/β proteins have been shown to inhibit 
phorbol-ester-mediated NF-κB activation.  IKK activation and expression 
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may vary in different cell lines or under different growth conditions, 
resulting in conflicting results (Perkins, 2000). 
 
 
1.4 ACTIVATION OF IKK BY THE PI3-KINASE/AKT 
PATHWAY 
 
The PI3-kinase/Akt pathway has been linked to three main biological 
processes vital to the progress of cancer development, survival, 
proliferation and cell growth.  As previously mentioned, there is an 
increasing number of downstream targets responsible for the development 
and survival of cancer cells (Okano et al, 2002; Vivanco & Sawyers, 
2002).  In this study, one biological process, survival, and one 
downstream pathway; IKK, IκB and NF-κB, was highlighted for analysis.  
 
With the binding of an appropriate ligand to the RTK, SH2 domains on the 
p85 subunit of the preformed inactive PI3-kinase complex bind to the 
phospho-tyrosine residues on the receptor.  This brings the p110 catalytic 
in close proximity to its substrate, PtdIns(4,5)P2.  PI3-kinase 
phosphorylates PtdIns(4,5)P2 at the D3 position forming the second 
messenger PtdIns(3,4,5)P3, which is necessary for the binding of Akt’s 
pleckstrin-homology domain (Fig 1.2).  Akt is recruited to the membrane, 
where it binds to PtdIns(3,4,5)P3, and an unknown kinase phosphorylates 
and releases the inhibitor CTMP.  The binding of Akt to PtdIns(3,4,5)P3 
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conformationally changes Akt, exposing Thr308 which is phosphorylated 
by PDK-1.  This phosphorylation is necessary and sufficient for Akt 
activation, however maximum activation is achieved with the 
phosphorylation of Ser473 by PDK-2.   Akt is then able to activate its 
downstream pathways, including IKK which is phosphorylated on the IKKα 
subunit at Ser180 and on the IKKβ subunit at Ser181.  Phosphorylated 
IKK in turn phosphorylates IκB on Ser 32 and Ser36 resulting in the 
release of NF-κB.  The phosphorylated IκB is ubiquitinated and degraded 
by the 26S proteosome (Franke et al, 1997; Frech et al, 1997; Okano et 
al, 2000; Brazil & Hemmings, 2001; Vivanco & Sawyers, 2002; Brazil et al, 
2004).  This allows NF-κB to move from the cytoplasm to the nucleus 
where it activates the transcription of anti-apoptotic genes including those 
involved in the regulation of inflammation and immune responses, viral 
replication, nitric oxide production, cell-cell interactions, apoptosis and 
proliferation (Fig 1.4) (Franke et al, 1997; Frech et al, 1997; Janssen-
Heininger et al, 2000; Okano et al, 2000; Ryan et al, 2000; Brazil & 
Hemmings, 2001; Vivanco & Sawyers, 2002; Brazil et al, 2004).      
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Figure 1.4 The proposed PI3-kinase/Akt pathway showing the activation 
of IKK, IκB and IKK. 
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1.5 CHEMICAL INHIBITORS OF THE PI3-KINASE/AKT 
PATHWAY 
 
Identification of specific inhibitors is extremely useful in the 
characterisation of intracellular signalling cascades or networks.  Two 
specific PI3-kinase pathway inhibitors, wortmannin and LY294002, have 
been extensively used to define the role of this kinase and its products in 
cells, however many new inhibitors are being developed and tested daily. 
 
1.5.1 WORTMANNIN 
 
Wortmannin is a fungal metabolite which has been shown to specifically 
inhibit the PI3-kinase pathway.  Many specific inhibitors are unable to pass 
through the cell membrane, however wortmannin is cell-permeant which 
allows whole cell studies to be performed on the PI3-kinase pathway.  
Wortmannin binds covalently and irreversibly to the p110 catalytic subunit 
of the PI3-kinase molecule (Ui et al, 1995).  It has recently been found 
that L802 present in the kinase domain of PI3-kinase in conjunction with 
wortmannin covalently modifies the β-phosphate of ATP to a Schiff base, 
preventing phosphorylation (Steelman et al, 2004).     
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1.5.2 LY294002 
 
2-(4-Morphylinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002) was first 
described by Vlahos and colleagues in 1994, when they synthesised 
several chromones from the initial and relatively unsuccessful PI3-kinase 
inhibitor, quercetin.  One of these chromones, LY294002, was found to be 
a selective inhibitor of PI3-kinase with a 2.7-fold greater potency than 
quercetin.  LY294002 is a competitive inhibitor of the ATP-binding site of 
PI3-kinase, however does not inhibit several other ATP-requiring 
enzymes, unlike quercetin (Vlahos et al, 1994).   
 
In a recent study, treatment of cells with LY294002 resulted in 
dephosphorylated Akt and BAD in leukaemic cell lines and AML as well as 
decreased clonogenic growth of the AML cells.  This inhibition of colony-
forming was less pronounced in normal myeloid progenitor cells signifying 
that LY294002 may selectively target leukaemic cells over normal 
haemopoietic cells.  This is indicative that inhibition of the PI3-kinase 
pathway with LY294002 may have significant therapeutic implications in 
AML therapy (Zhao et al, 2004). 
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1.5.3 OTHER PI3-KINASE INHIBITORS 
 
Many scientific groups have deemed wortmannin and LY294002 
unsatisfactory in the inhibition of PI3-kinase, as downstream kinases that 
are dependent on PI3-kinase activity are also presumably inactivated.  An 
Akt inhibitor 1L-6-hydroxy-methyl-chiro-inositol 2(R)-2-O-methyl-3-O-octa-
decylcarbonate described by Martelli and co-workers (2003), has been 
shown to decrease the resistance of leukaemic cells to cytotoxic drugs 
and ionizing radiation.  A plant derived pigment called curcumin, was used 
to inhibit prostrate cancer cell growth, and was shown to reduce Akt 
phosphorylation on Ser473.  Degeulin was synthesised from the natural 
plant compound rotenone, and was found to inhibit human bronchial 
epithelial cell proliferation.  The constitutively activated Akt in this cell line 
was inhibited by degeulin without interfering with the PI3-kinase activity.  
Meuillet and colleagues (2003) identified a group of D-3-deoxy-
phospatidyl-myo-inositols that traps Akt in the cytosol, and prevents its 
activation by binding to its PH domain (Brazil et al, 2004). 
 
The increased specificity being discovered with these new inhibitors lays a 
platform for the further advancement in our understanding of the PI3-
kinase pathway.  Pro-survival pathway inhibitors used in conjunction with 
cytotoxic drugs to obtain a higher percentage of apoptosis, may prove 
useful in the future both in the laboratory and in the clinic.   
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1.6 APOPTOSIS AND NECROSIS 
 
An important part of the development, maintenance and growth of a tissue 
is the ability to control the death of damaged cells.  There are two distinct 
types of cell death, the first being an accidental cell death or necrosis, 
which can be induced by lethal physical, chemical or biological injury.  The 
second is programmed cell death (PCD) otherwise known as apoptosis 
(Vermes et al, 1997; Story & Kodym, 1998). 
 
1.6.1 NECROSIS 
 
Necrosis is not seen in normal tissue development, but occurs in response 
to injury or toxic damage.  The process of necrosis is not biologically 
controlled and starts when the cell membrane is damaged.  This results in 
the disruption of osmotic homeostasis as the selective permeability and 
ion-pumping capacity of the cell membrane is lost.  The influx of cations 
causes an almost instantaneous swelling of the cell and its organelles, the 
cellular metabolic pathways collapse and poisoning of respiration 
pathways occur.  Random DNA degradation and further membrane 
disruption occurs with the activation of Ca2+-dependent degradative 
enzymes, such as phospholipases, hydrolases, proteases and 
endonucleases.  The cell eventually bursts due to the osmolytic 
imbalance, and a cache of lysosomal and degradative enzymes are 
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released.  These elicit an inflammatory response in the adjacent viable 
cells and can result in a zone of necrotic cells radiating from a necrotic 
centre in a tissue (McKenna, 1996; Vermes et al, 1997; Story & Kodym, 
1998; Golstein et al, 2003).        
 
1.6.2 APOPTOSIS 
 
Programmed cell death (PCD) was first described by Kerr, Wyllie and 
Currie in 1972.  They named the natural ordered elimination of cells from 
a tissue apoptosis, which, in classic Greek describes the loss of leaves 
from a tree in autumn (McKenna, 1996; Story & Kodym, 1998).  Apoptosis 
is a genetically mediated form of cell death and plays an integral role in 
normal tissue development.  It is involved in organogenesis, tissue 
homeostasis and remodelling, and the removal of auto-reactive clones by 
editing of the immune system.  In contrast to necrosis, which affects a 
large number of cells in one area, apoptosis characteristically affects 
scattered individual cells and usually does not cause an inflammatory 
response (McKenna, 1996).  The process of apoptosis has been 
described as an active bio-energy saving cell-elimination mechanism, 
which removes aged, unwanted or damaged cells.  The cellular contents 
of precious caloric value are phagocytosed by adjacent cells or 
macrophages and recycled (Vermes et al, 1997).   
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1.6.1.1 Morphology of Apoptotic Cells 
 
Apoptosis occurs by a specific pattern and is characterised by several 
distinct morphological changes.  One of the first changes is the severing 
of junctions with neighbouring cells and the loss of specialised membrane 
structures such as microvilli.  The integrity of the cell membrane and the 
mitochondria however, remains initially intact.  The cytoplasm and nucleus 
become condensed and the chromatin aggregates along the nuclear 
membrane. Degradation at the internucleosomal linker sites of the cellular 
DNA yields fragments in multiples of 180 base pairs giving the nucleus a 
segmented appearance.  The membrane appears to be blebbing and 
convoluted as the endoplasmic reticulum is transformed in to vesicles, 
which fuse to the cellular membrane.  The cell membrane becomes rigid 
due to the cross-linking of the membrane proteins before the cell is broken 
apart into small vesicles called apoptotic bodies.  The apoptotic bodies 
contain remnants of the cell as well as several apparently intact 
organelles. These remain in the extracellular space until they are 
phagocytosed by the neighbouring cells or by the macrophages (Vermes 
et al, 1997; Story & Kodym, 1998; Corfe, 2002; Golstein et al, 2003).   
 
No damage to the surrounding cells occurs, and no inflammatory 
response is initiated during apoptosis.  This is due to the surface changes 
on the apoptotic cells and the appropriate receptors on the macrophages 
and neighbouring phagocytic cells.  There is increasing evidence that a 
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phosphatidyl-serine (PS) flip-flop phenomenon occurs in apoptotic cells, 
and that the exposed PS may act as a recognition site for the phagocytic 
cells.  It is also thought that this change in architecture of the cell 
membrane and the altering of the surface hydrophobicity and charge may 
be recognised by the macrophages (Vermes et al, 1997; Corfe, 2002). 
 
1.6.1.2 The Apoptotic Pathways 
 
Although apoptosis may be triggered by a wide variety of stimuli, there are 
essentially two pathways that control this process.  The first can be 
thought of more as murder than suicide.  Cells contain a large number of 
receptors on the surface membrane, and several of them are death 
receptors.  The presentation of an appropriate ligand for a death receptor 
causes these to form a multi-protein complex called the death-induced 
signalling complex (Fig 1.5).  This complex triggers the direct activation of 
caspase-8, which belongs to a proteinase family known as the caspases.  
The caspases are thought to be activated solely and specifically during 
apoptosis.  Certain caspases can auto-activate and can then activate 
other caspases and a variety of other cellular substrates.  These are 
involved in the breaking down and packaging of the cellular components 
into apoptotic bodies (Vermes et al, 1997; Green & Reed, 1998, 
Thornberry & Lazenbnik, 1998; Li & Yuan, 1999; Adrain & Martin, 2001). 
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The second pathway involves intracellular signalling that targets the 
mitochondria, where several of the Bcl-2 protein family members are 
situated.  These include proapoptotic Bak and Bax, and the anti-apoptotic 
Bcl-xL and Bcl-2 proteins. Bcl-xL and Bcl-2 may also be present in the 
endoplasmic reticulum and the nuclear membrane in some cell types, and 
often Bax is found in the cytosol.  Once apoptosis is stimulated Bax is 
recruited to the mitochondria where it binds to Bak (Fig 1.5).  This complex 
forms pores in the membrane, allowing the release of cytochrome c into 
the cytoplasm and the loss of mitochondrial membrane potential.  The 
apoptosome, a protein complex of pro-caspase 9 and APAF-1, binds with 
the released cytochrome c.  This leads to the activation of caspase-9, 
which activates pro-caspase 3 and 7 and the other apoptotic substrates in 
the same manner of the first pathway (Vermes et al, 1997; Green & Reed, 
1998, Thornberry & Lazenbnik, 1998; Li & Yuan, 1999; Adrian & Martin, 
2001; Pommier et al, 2004) (Fig 1.5).   
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Figure 1.5 A diagrammatic representation of the two apoptotic 
pathways 
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1.7 THE CYTOTOXIC DRUG ETOPOSIDE 
 
Doxorubicin and etoposide are both topoisomerase II inhibitors, and are 
both active chemotherapeutic agents used in clinical oncology, particularly 
in breast cancer and leukaemia, respectively.  The exact mechanism of 
etoposide’s antineoplastic effect is unknown, however there are two 
theories.  The first is that it acts at the premitotic stage of cell division to 
inhibit DNA-synthesis.  This is cell cycle-dependent and phase-specific as 
it has maximum effect on the S and G2 stages of cell division.  The second 
theory is that the topoisomerase II inhibition results in DNA damage, 
causing cytochrome c to be released from the mitochondria. This is 
followed by the activation of caspase 9 and the effector caspases that 
were previously described (Fig. 1.5) (Yang et al, 2001; USP DI(R) Drug 
Information for the Health Care Professional, 2003). 
 
Treatment of patients with etoposide has been shown to cause acute 
leukaemia (onset 2 to 3 years), therefore the risk-benefit must be carefully 
considered by the health care professional.  Etoposide is generally used in 
life-threatening situations or in serious diseases for which other 
medications cannot be used or are ineffective (USP DI(R) Drug 
Information for the Health Care Professional, 2003). 
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1.8 THE HL-60 PROMYELOCYTIC LEUKAEMIA CELL LINE 
 
The HL-60 cell line was derived from a 36-year-old Caucasian female with 
acute promyelocytic leukaemia (APL).    This cell line has proved to be 
valuable in several areas of research as the cells proliferate continuously 
in suspension culture with a doubling time of ~36 to 48 hours.    The cells 
can also be induced to differentiate into four different cell types; 
granulocytes, monocytes, macrophage-like cells and eosinophils, using 
various agents (Collins, 1987). 
 
HL-60 cells have proven to be invaluable in the study of oncogenic 
structure and expression in normal and leukaemic cell proliferation and 
differentiation.  The cell line exhibits several specific genomic mutations 
involving the cellular oncogenes c-myc, N-ras and p53.  This reinforces 
the concept that the development of cancer is from a series of genomic 
mutations (Collins, 1987). 
 
 
1.9 OBJECTIVES OF THIS STUDY 
 
Drug resistance is proving to be a serious limiting factor in the treatment of 
many leukaemias.  O’Gorman and co-workers (2000) recently 
demonstrated that an increase in apoptosis resulted in response to 
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cytotoxic drugs after the inhibition of the PI3-kinase pathway.  They 
studied the regulation of BAD in relation to the PI3-kinase/Akt pathway 
and found no changes.  Thus they postulated that alternate targets of Akt 
may be responsible for drug resistance in AML (O’Gorman et al, 2000).  
This project aims to determine whether inhibition of the PI3-kinase 
pathway results in increased apoptosis in HL-60 cells, and to determine 
the role of IKK in the prevention of apoptosis. 
  
The specific aims of the project are: 
1. To monitor cell growth/survival when HL-60 cells were treated with 
PDGF and etoposide in conjunction with LY294002. 
2. To determine qualitatively (confocal microscopy and DNA 
fragmentation) and quantitatively (flow cytometry) whether HL-60 
cells undergo apoptosis when treated with the cytotoxic drug 
etoposide and/or LY294002. 
3. To investigate the expression of Total Akt, activated Akt 
(phosphorylated) and its mRNA, phospho-IKK and phospho-IκB in 
HL-60 cells after exposure to: 
(i) growth factors (PDGF) 
(ii) inducers of apoptosis (etoposide) 
in the presence and absence of PI3-kinase inhibitor LY294002. 
 
These aims will help to demonstrate the roles that Akt and IKK play in the 
prevention of apoptosis in HL-60 cells. 
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CHAPTER 2 
 
MATERIALS AND METHODS 
 
2.1 HL-60 CELL CULTURE 
 
The sources of all the chemicals and equipment used are listed in 
Appendix 1.1 and the preparation of the reagents used for culturing are 
described in Appendix 2.1. 
 
2.1.1 MAINTENANCE CULTURE CONDITIONS 
 
The Human leukaemic cell line HL-60 was purchased from the American 
Type Culture Collection (Maryland, USA). The cells were grown in a 
humidified atmosphere of 5% CO2: 95% air at 37°C.  Tissue culture flasks 
were used to maintain the cells in sterile-filtered RPMI-1640 medium.  The 
medium contained 22 mM NaHCO3, 100 U/L penicillin, 100 µg/L 
streptomycin and 2.5 mg/L fungizone with 10% heat-inactivated foetal calf 
serum (FCS).  RPMI-1640 medium stored for more than 3 weeks was 
resupplemented with 2mM glutamine, as it has a half-life of 3 weeks.  
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2.1.1.1 Passaging and feeding cells  
 
HL-60 cells are a non-adherent cell line and have a doubling time of ∼36-
48 hours.  Every two days the cells were allowed to settle, and 
approximately half of the used medium was poured off and replaced with 
fresh medium.  Once the cells had reached confluence, they were 
passaged into fresh culture flasks at a split ratio of 1:5.  The cultures were 
regularly examined using light microscopy (200x) for morphological signs 
of cellular damage or deterioration. 
 
2.1.1.2 Cell counting and viability determination 
 
The cells were counted and the viability determined using the trypan blue 
exclusion test.  Cells (100µl) were removed from the culture flask and 
added to an equal volume of trypan blue dye.  The cell suspension (100 
µl) was placed in a haemocytometer and examined at 200x magnification.  
All of the unstained cells in the central square of the grid were counted.  
The volume of the grid is 10-4 ml therefore the number of cells per ml 
could be determined. 
 
No. cells/ml = No. cells in central grid x 104 x dilution factor 
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The viability of the cells was determined by counting the number of blue-
stained dead cells in the central grid.  The percentage of unstained viable 
cells to blue-stained dead cells could then be calculated. 
 
2.1.1.3 Cell cryopreservation and recovery 
 
At regular intervals cells were removed from the cultures and stored 
frozen at -70°C.  The cells were allowed to grow to the late log phase 
when they were at high confluence.  A volume containing approximately 
10 x 106 cells was removed from the flasks and the cells pelleted by 
centrifuging at 500 rpm for 5 minutes at 20°C.  The medium was 
discarded and the cells resuspended in 1 ml FCS.  An equal volume of 
freezing mixture consisting of 40% sterile glycerol and 60% culture 
medium was added.  The cell suspension was then transferred into sterile 
cryotubes and frozen slowly, wrapped in cotton wool at -20°C overnight 
and then stored at -70°C until required.    
 
The cells were recovered from frozen storage by rapidly thawing in a water 
bath at 37°C.  Ten volumes of warm culture medium were added drop-
wise to the cell solution reducing osmotic shock.  Centrifugation (500 rpm 
for 5 min at 20°C) was used to remove the freezing solution, and the cells 
were resuspended in 10 ml of fresh culture medium.  The cells were 
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placed in a small sterile tissue culture flask and maintained as previously 
described.      
 
2.1.2 CULTURE CONDITIONS OF EXPERIMENTS 
 
For use in experiments, the HL-60 cells were counted (Chapter 2.1.1.2) 
and the appropriate number of cells for the experiment (refer to specific 
experiments) were placed in sterile Nunc tubes.  The medium was 
removed by centrifuging at 500 rpm for 5 min (20°C).  The cells were 
resuspended in RPMI-1640 with 10% FCS without fungizone, as it 
interferes with etoposide, and placed in sterile petri dishes.  The cells 
were stimulated with various agents (Chapter 2.2) and then placed in 
sterile Nunc tubes and centrifuged at 2000 rpm for 10 min (4°C).  The 
pellets were washed three times by resuspending in PBS and centrifuging 
at 4°C for 10 min (2000 rpm).  The washed pellets were resuspended in 
the appropriate buffer for each experiment. 
 
 
2.2 STIMULATION OF CELLS 
 
The suppliers of all the chemicals are listed in Appendix 1.2, and the 
preparation of all the reagents is described in Appendix 2.2. 
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2.2.1 PLATELET DERVIVED GROWTH FACTOR 
 
A stock solution of Platelet Derived Growth Factor (PDGF) (10 ng/µl) was 
dissolved in 4 mM HCl + 0.1% BSA.  Cells (20 x 106) were plated into 15 
mm sterile petri dishes in a final volume of 2 ml.  The cells were incubated 
with 50 ng/ml PDGF for 15 min and 30 min as these times were found to 
give optimal phosphorylation of Akt.  Two controls were prepared, the first, 
the blank had no stimulants added, and in the second the cells were 
incubated for 30 min with HCl-BSA at the same concentration as the 
experimental samples.  This was done to ensure that the PDGF and not 
the HCl-BSA were responsible for the results obtained. 
 
2.2.2 APOPTOSIS INDUCING AGENTS 
 
Two different apoptosis inducing agents were used: (i) Cyclohexamide 
was used primarily as a positive control as literature cites it as causing 
apoptosis in HL-60 cells and (ii) the chemotherapeutic drug etoposide. 
Stock solutions of cyclohexamide and etoposide were prepared at 3 
mg/ml and 30 mg/ml in DMSO respectively.  DMSO at the same 
concentration as the cytotoxic agents was added to the controls.  
Cyclohexamide (3 µg/ml) and etoposide (60 µg/ml) were incubated with 
the cells for 4, 24 and 48 hrs depending on the experiment.   
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2.2.3 THE PI3-KINASE INHIBITOR - LY294002 
 
LY294002 was dissolved in DMSO and added at 25 µM 1 hour prior to the 
addition of PDGF and the apoptosis inducers.  In the experiments with 
PDGF, an extra control was set up with both DMSO and HCl-BSA.  
 
2.2.4 NECROSIS POSITIVE CONTROL 
 
It is important to have a necrosis positive control with which to compare 
the experimental results.  The necrosis control was prepared by plating 
the cells in an identical manner to the samples for the experiment.  The 
cells were then subjected to 6 cycles of freeze/thawing at -70°C for 5 
minutes each.  
 
 
2.3 GROWTH/CYTOTOXICITY ASSAY 
 
This assay is a rapid method allowing viable cell number to be determined 
in proliferation, cytotoxicity, cell attachment, chemotaxis and apoptosis.  
Mosmann first described the original form of this assay, the MTT assay, in 
1983.  The MTT assay has many problems including serum protein 
precipitation caused by the addition of organic solvent, interference of 
phenol red, incomplete solubilization of formazan crystals resulting in a 
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lowered sensitivity and the stability of the coloured product.  Many of these 
problems have been solved by the use of the CellTitre 96 Non-
Radioactive Cell Proliferation Assay kit (Promega).  
 
The source of the kit and reagents used are listed in Appendix 1.3.  The 
dilutions used are described in Appendix 2.3. 
 
2.3.1 HARVESTING OF CELLS FOR ASSAY 
 
Cells (4 x 106 cells) were removed from the flasks and centrifuged at 
500rpm (20°C) for 5 minutes.  The medium was removed and the cells 
resuspended in 2 ml of 10% FCS RPMI.   
 
2.3.2 PREPARATION OF ASSAY PLATES 
 
2.3.2.1 Proliferation Assay 
 
The effects of PDGF (10, 30, 50, 70 and 90 ng/ml) with and without 25 µM 
LY294002 were evaluated in this assay.  Stock solutions (4X) of HCl-BSA, 
DMSO, LY294002 and PDGF (at each concentration) were prepared in 
10% FCS RPMI.  Stock solutions (25 µl) of HCl-BSA (in triplicate), DMSO 
(in triplicate) and PDGF (two sets in triplicate) were added to the wells of a 
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sterile 96 well plate (Fig. 2.1).  To each well, 25 µl 10% FCS RPMI was 
added except one set of PDGF in triplicate, to which 25 µl stock LY294002 
was added.  Two blanks (in triplicate) containing 50 µl 10% FCS RPMI 
were prepared.  Thus the final volume in each well was 50 µl. 
 
 
             PDGF               PDGF + 25 µM LY294002 
 
10 
ng/ml 
30 
ng/ml 
50 
ng/ml 
70 
ng/ml 
90 
ng/ml 
10 
ng/ml 
30 
ng/ml 
50 
ng/ml 
70 
ng/ml 
90 
ng/ml 
10 
ng/ml 
30 
ng/ml 
50 
ng/ml 
70 
ng/ml 
90 
ng/ml 
10 
ng/ml 
30 
ng/ml 
50 
ng/ml 
70 
ng/ml 
90 
ng/ml 
10 
ng/ml 
30 
ng/ml 
50 
ng/ml 
70 
ng/ml 
90 
ng/ml 
10 
ng/ml 
30 
ng/ml 
50 
ng/ml 
70 
ng/ml 
90 
ng/ml 
Blank 
10 % 
FCS 
25 µM 
LY 
HCl-
BSA 
DMSO     
 
Blank 
10 % 
FCS 
25 µM 
LY 
HCl-
BSA 
DMSO     
 
Blank 
10 % 
FCS 
25 µM 
LY 
HCl-
BSA 
DMSO     
 
 
Figure 2.1 Schematic representation of the 96 well plate prepared for 
the proliferation assay 
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The cell suspension (50 µl (100 000 cells) prepared as described above 
(2.8.1), was added to each well, except one blank (in triplicate), where 50 
µl of medium was added.  The plate was incubated at 37°C in the 
incubator for 48 hours. 
 
2.3.2.2 Cytotoxicity Assay 
 
The percentage of cell survival was determined in this assay by the 
incubation of cells with five different concentrations of etoposide (20, 40, 
60, 80 and 100 µg/ml) with and without 25 µM LY294002.    
 
A 4X stock solution of DMSO, each concentration of etoposide and 
LY294002 was prepared in 10% FCS RPMI.  Stock solutions (25 µl) of 
DMSO (in triplicate), and etoposide (two sets in triplicate) were added to 
the wells of a sterile 96 well plate (Fig 2.2).  To each of the above wells 25 
µl of 10% FCS RPMI was added, except the second set of etoposide 
concentrations, to which 25 µl LY294002 stock was added.  Two blanks 
(in triplicate) were prepared by adding 50 µl 10% FCS RPMI to the wells.  
The final volume of each well was 50 µl. 
 
The cell suspension (50 µl (100 000 cells) prepared as previously 
described (Chapter 2.2.1), was added to each well, except one blank (in 
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triplicate), where 50 µl of medium was added.  The plate was incubated at 
37°C in the incubator for 48 hours. 
   
Etoposide         Etoposide + 25 µM LY294002 
 
20 
µg/ml 
40 
µg/ml 
60 
µg/ml 
80 
µg/ml 
100 
µg/ml 
20 
µg/ml 
40 
µg/ml 
60 
µg/ml 
80 
µg/ml 
100 
µg/ml 
20 
µg/ml 
40 
µg/ml 
60 
µg/ml 
80 
µg/ml 
100 
µg/ml 
20 
µg/ml 
40 
µg/ml 
60 
µg/ml 
80 
µg/ml 
100 
µg/ml 
20 
µg/ml 
40 
µg/ml 
60 
µg/ml 
80 
µg/ml 
100 
µg/ml 
20 
µg/ml 
40 
µg/ml 
60 
µg/ml 
80 
µg/ml 
100 
µg/ml 
Blank 
10 % 
FCS 
25 µM 
LY 
DMSO       
Blank 
10 % 
FCS 
25 µM 
LY 
DMSO       
Blank 
10 % 
FCS 
25 µM 
LY 
DMSO       
 
Figure 2.2 Schematic representation of the 96 well plate prepared for 
the cytotoxicity assay 
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2.3.3 COLOUR DEVELOPMENT  
 
Dye solution (15µl) was added to each well and the plates were incubated 
for 4 hours at 37°C at 5% CO2, to allow the formation of the formazan 
crystals.  After 4 hours, 100µl of the Solubilizing/Stop solution was added.  
It was no longer necessary to keep the plate sterile and it could be 
incubated at room temperature for 1 hour, but better solubilization 
occurred at 37°C.  After 1 hour, the contents of the wells were gently 
mixed using a multichannel pipette and care was taken to prevent the 
formation of bubbles.  The plate was placed in the 96 well plate reader 
and the plate was gently shaken for 30 seconds to ensure a uniformly 
coloured solution. The absorbance was read at 570nm, as the maximum 
absorbance for formazan is 570nm.  A reference wavelength of 630nm 
was used to reduce background contributed by cell debris, fingerprints and 
other nonspecific absorbance. 
 
The plate was allowed to stand overnight in a humidified chamber at room 
temperature to completely solubilize the formazan crystals.  The 
absorbance readings were then taken again and compared with the first 
readings. 
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2.4 PROTEIN EXTRACTION PROTOCOLS 
 
The suppliers for the chemicals used are listed in Appendix 1.4 and the 
preparation of the buffers is described in Appendix 2.4. 
 
The extraction of protein from cells is a very important first step in 
analysis, and therefore the choice of extraction buffer and method is 
important.  This is to ensure that the target proteins are immunoreactive 
and undegraded.  A small-scale pilot study was conducted using five lysis 
buffers (Table 2.1) with two extraction techniques to determine which 
buffer and method gave optimal protein concentration and the least 
protein degradation.   
 
Two Protocols were used for protein extraction. 
 
2.4.1 PROTOCOL 1 
 
This protocol was used for lysis buffers: A, B, D, and E. The cells were 
counted (Chapter 2.1.1.2) and 20 x 106 cells were seeded in 60 mm petri 
dishes.  After stimulation (Chapter 2.2) the cells were washed as 
previously described in 2.1.2. Lysis buffer (100 µl) was added to the cells 
and placed in an Eppendorff tube. The cells were lysed with an initial 15 
minutes of freezing at -70°C.  This was followed with 3 cycles of freeze 
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thawing of 5 min each.  The lysates were centrifuged in a bench top 
centrifuge at 14 000 rpm (4°C) for 3 min, the pellet was discarded, to 
obtain a supernatant with dissolved proteins. An equal volume of loading 
buffer was added to each sample and then boiled at 100°C for 3 min. The 
samples were stored at -70°C until required for electrophoresis. 
 
2.4.2 PROTOCOL 2 
 
This protocol was used for lysis buffer C.  The cells were counted 
(Chapter 2.1.1.2) and 20 x 106 cells were seeded in 60 mm petri dishes.  
After the cells were stimulated (Chapter 2.2) they were washed as 
previously described in Chapter 2.1.2. The cells were resuspended in 100 
µl lysis buffer C and the DNA was sheared by sonicating the sample, while 
on ice, for 13 seconds at high frequency.  The extracts were boiled for 5 
min, and then centrifuged in an Eppendorff microcentrifuge at 4°C for 5 
min.  The pellet was discarded, obtaining a supernatant with dissolved 
proteins. The samples were stored at -70°C until required for 
electrophoresis. 
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Table 2.1 Composition of lysis buffer used in protein extraction from 
HL-60 cell culture   
 
BUFFERS COMPOSITION 
 
Buffer A 
 
20 mM Tris-HCl (pH 7.5), 0.25 M Sucrose, 1% Triton X-100 
 
Buffer B 
 
20 mM Tris-HCl (pH 7.5), 0.25 M Sucrose, 1% Triton X-100, 1 mM PMSF 
 
Buffer C 
(SDS-lysis buffer) 
62 mM Tris-HCl (pH 6.8), 2% SDS, 10% glycerol, 0.5%  
β-mercaptoethanol 
 
Buffer D 
 
20 mM Tris-HCl (pH 7.5), 100 mM NaCl, 1% Triton X-100, 0.1% SDS,  
1 mM Na3VO3, 1 mM PMSF, 50 mM NaF 
 
Buffer E 
(Akt lysis buffer)  
20 mM Tris-HCl (pH 7.2), 150 mM NaCl, 10% glycerol, 1% Triton X-100, 10 mM 
NaF, 30 mM Sodium pyrophosphate, 1 mM EDTA, 1 mM Na3VO3, 1 mM PMSF 
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2.5 TOTAL PROTEIN DETERMINATION 
 
The Lowry-Folin technique was used to determine the concentration of the 
protein samples.  The sources of the chemicals used are listed in 
Appendix 1.5, and the preparation of all the reagents are described in 
Appendix 2.5.  All standards and samples were performed in duplicate. A 
standard curve was prepared with bovine serum albumin (BSA). Protein 
concentrations of 0, 25, 50, 75, 100 and 150 µg were prepared in 1 ml of 
distilled water.  SDS interferes with the reaction, therefore for the proteins 
extracted with lysis buffer C, 10 µl of the lysis buffer was added to each of 
the standards of the standard curve.  Each sample (10 µl) was added to 
990 µl of distilled water.  Working Reagent A was freshly prepared by 
adding the following components in strict order with constant stirring: 1 ml 
2% w/v sodium potassium tartrate, 1 ml 1% w/v copper sulphate and 100 
ml 2% sodium carbonate in 0.1 M NaOH. Working reagent A (5 ml) was 
added to each tube then vortexed and allowed at stand for 15 min at room 
temperature.  A 1:1 dilution of Folin & Ciocalteau Reagent was freshly 
prepared with distilled water, and 0.5 ml was added to each tube.  The 
samples were vortexed and placed in the dark for 30 min allowing a 
characteristic blue colour to develop.  
 
The absorbance was read at 750 nm on the Beckman DU-65 
spectrophotometer using the Lowry-Folin program.  A standard curve was 
constructed by plotting the protein concentration of each standard against 
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the absorbance reading.  Total protein concentration of each sample was 
determined by plotting the absorbance reading of the sample against the 
standard curve. 
 
 
2.6 SDS-PAGE ELECTROPHORESIS 
  
The suppliers of the chemicals used for SDS-PAGE are listed in Appendix 
1.6, and the preparation of reagents, stacking and resolving gels, 
molecular weight markers, buffers and stains are described in Appendix 
2.6.   
 
A mini gel system was used for electrophoresis.  The dimensions of each 
gel were 8 cm x 10 cm with a thickness of 1.5 mm.  All components of the 
apparatus were thoroughly washed, and rinsed with distilled water and 
then with 70% ethanol to remove any contaminants.   
 
The percentage gel used is dependent on the size of the protein in 
question.  The higher the percentage of the gel, the smaller the pore 
sizes.  For example, a 15% gel separates proteins with a Mr in the range 
of 100 000 to 10 000.  Generally a 12.5% resolving gel with a 4% stacking 
gel was poured. 
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Identical concentrations (40 µg) of the protein samples were added into 
the wells of each gel using a microtitre syringe.  Protein molecular weight 
markers (5µl), treated in the same manner as the protein lysates, were 
also run on the gels.  
 
The electrophoresis unit was attached to a cooling system that was set to 
4°C before running the gels.  A Hoefer Scientific Instruments power pack 
was used to run each gel at 10 mA for ±1 hour (or until through the 
stacking gel).  Thereafter the gels were run at 15 mA per gel for ±2 hours.   
 
Once the dye front had reached the bottom of the resolving gel, the power 
pack was switched off and the gels removed.  The gels were stained for 
protein with Coomassie Brilliant Blue R-250 stain followed by an overnight 
incubation in destain or western blotted onto nitrocellulose paper for 
immunodetection.    
 
 
2.7 WESTERN BLOTTING 
 
The source of the materials used is described in Appendix 1.7 and the 
details regarding the preparation of the reagents are given in Appendix 
2.7.   
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The gels were removed from between the plates and gently washed with 
tap water to remove any excess SDS that might hinder the transfer.  
Nitrocellulose paper was cut to the same size as the gel, care was taken 
ensuring that the nitrocellulose was not touched to avoid contamination.  
Both the gel and the paper were equilibrated in the transfer buffer to 
remove any excess SDS and air bubbles.  This also reduces the 
possibility of band distortion and poor resolution.  
 
The cartridge was assembled, by placing the gel and the nitrocellulose 
between two sponges and four pieces of filter paper. All air bubbles were 
removed from the sponges, before the cassette was closed and placed in 
the Transfer Electrophoresis Unit TE series with the membranes facing 
the anode (positive electrode) and the gel facing the cathode (negative 
electrode).  The gel was transblotted at a constant current of 200 mA 
(maximum voltage) for 2 hours at 4°C.  
 
Once completed the blots were either stained with Amido black stain for 1 
hour and placed in destain overnight or immunoblotted. 
 
  
  
 
 
  59 
2.8 IMMUNOBLOTTING 
 
The sources of the chemicals are listed in Appendix 1.8, and the 
preparations of the reagents used for immunoblotting are described in 
Appendix 2.8.  Details of the concentrations of the four antibodies and the 
blocking buffers used are described in Table 2.2. 
 
After the transfer of protein from the SDS-PAGE to the nitrocellulose, all 
the membranes were trimmed to prevent a background outline.  The 
membranes were washed in TBS-T for 5 minutes at room temperature to 
remove the excess transfer buffer.  Incubating with freshly prepared 
respective blocking buffers for 1 hour at room temperature blocked any 
non-specific binding sites on the membrane. The primary antibodies were 
diluted in freshly prepared primary antibody dilution buffer.  This was 
placed with the membranes in glass petri dishes and incubated overnight 
at 4°C with gentle agitation.  The blots were washed six times (5 min 
each) with TBS-T.  The secondary antibodies were diluted in freshly 
prepared secondary antibody dilution buffer and incubated with the 
membrane for 1 hour at room temperature with gentle agitation.  The blots 
were washed six times (10 min each) in TBS-T. 
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Table 2.2 The four antibodies used, their concentrations and blocking 
buffers 
 
1° Antibody Type 
Blocking 
Buffer 
1° Ab Dilution 2° Antibody 2° Ab Dilution 
Total Akt Poly-clonal BSA 1:75 000 
Donkey anti 
Rabbit 
1:100 000 
Phospho-Akt Poly-clonal BSA 1:25 000 
Donkey anti 
Rabbit 
1:100 000 
IκB Mono-clonal Milk powder 1:50 000 
Sheep anti 
Mouse 
1:100 000 
IKK Poly-clonal BSA 1:25 000 
Donkey anti 
Rabbit 
1:100 000 
 
 
All four proteins; Total Akt, Phospho-Akt, Phospho-IκB and Phospho 
IKKα/β were detected using the enhanced chemiluminescence technique 
(Whitehead et al, 1979). The Advanced ECLTM kit was used for detection, 
and the protocol was carried out in the dark room following the provided 
instructions. After washing the membranes in TBS-T, the excess TBS-T 
was drained and the membrane was placed on plastic cling film, with the 
protein side up.  Equal volumes (500 µl) of ECL Detection Solution 1 and 
Solution 2 (final volume required is 125 µl/cm2 membrane) were mixed 
and added to the membrane. The membrane was incubated for 1 min at 
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room temperature, before the excess reagent was drained off and the blot 
wrapped in a fresh piece of cling film.  All air pockets were gently 
smoothed out, and the membrane placed protein side up in a film 
cassette.  This was exposed to X-ray film for 2, 10 and 30 seconds and 1 
min. The film was removed and developed.  Depending on the intensity of 
the bands, the film may be exposed to a fourth piece of film for 2 minutes 
or longer. 
 
 
2.9 CONFOCAL MICROSCOPY 
 
Apoptosis can be detected by morphological changes according to the 
method described by Gibson and colleagues (1999).  The assay was used 
to detect the morphological changes in cells treated with etoposide, 
cyclohexamide and LY294002. The technique allows the different stages 
of apoptosis and necrosis to be visualised by the differential uptake of two 
fluorescent DNA binding dyes.  Acridine orange (AO) appears green and 
can be taken up by viable cells.  Ethidium bromide (EB) is an orange dye 
and can only enter the cell once the cell membrane has been 
compromised.  Healthy cells (H) therefore appear green, early apoptotic 
cells (EA) also appear green but condensation of the nucleus is very 
apparent as a solid green mass.  Once the cells have entered late 
apoptosis (LA), the membrane has lost its selective permeability and 
ethidium bromide can enter.  These cells can still appear green, but they 
  62 
are more commonly an orange colour with the nuclear material appearing 
as large orange granules.  The last stage of apoptosis is the packaging of 
the cellular contents into the apoptotic bodies.  These are orange but are 
often not visible.  Necrotic cells (N) are generally larger than healthy cells, 
and as the membrane is compromised they appear as large orange 
bodies (Fig. 4.6)     
 
The suppliers of all equipment and reagents used for confocal microscopy 
are listed in Appendix 1.9, and the preparation of the acridine orange-
ethidium bromide dye is described in Appendix 2.9.  Cells (1 x 106) were 
seeded in 15 mm petri dishes with a final volume of 1 ml, as previously 
described (Chapter 2.1.1.2).  After stimulation (Chapter 2.2) with various 
combinations of the inducers for 24 hrs, 20 µl of 100 mg/ml acridine 
orange and 100 mg/ml ethidium bromide in PBS was added to the cells.  
The cells were viewed at 40X magnification using the fluorescence 
microscope.  Photographs of 3 fields from each sample were taken and 
analysed.  
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2.10 FLOW CYTOMETRY 
 
Flow cytometry is a very precise and widely used technique.  Cells can be 
stained with a variety of different stains, before they are passed in single 
file through a stream of sheath fluid.  A focused laser beam is then 
directed at the cells, and depending on the granularity, nuclear 
condensation, membrane permeability and stain uptake, the light is 
scattered in different directions.  This allows specific cell populations in the 
sample to be isolated and quantitated (Glencross, 1994).   
 
This assay was based on the determination of membrane integrity and 
two stains; propidium iodide and YO-PRO-1 were used.  The normal 
healthy cells do not get stained by either dye, however the YO-PRO-1 dye 
binds to the exposed phosphatidyl-serine (PS) on the membranes of 
apoptotic cells.  Cells with intact or viable membranes do not allow 
propidium iodide to enter.  Once the cell becomes necrotic or the 
membrane is compromised, the propidium iodide enters the cell and 
stains the DNA.      
                  
The suppliers of all equipment and reagents used for flow cytometry are 
listed in Appendix 1.10, and the preparation of the solutions is described 
in Appendix 2.10.  As flow cytometry is a very sensitive technique it 
requires a relatively small number of cells (100 000).  Cells (1.5 x 106) 
were plated in 15 mm petri dishes.  After stimulation, as described in 
  64 
Chapter 2.2, for 48 hrs the cells were centrifuged at 1 000 rpm for 10 min 
at 20°C and resuspended in 1 ml of PBS.  From this approximately 3 x 105 
cells (200 µl) was resuspended in 800 µl of ice-cold PBS in flow cytometry 
tubes.  The remaining cells were used to determine DNA fragmentation.  
The samples were placed on ice and 0.5 µl of 1mM YO-PRO-1 and 1 µl of 
1mM propidium iodide were added.  The samples were gently vortexed, 
and incubated on ice for 20 min.  Control tubes were prepared with no dye 
added, and one was prepared with only YO-PRO-1 and another with just 
propidium iodide.  The samples were gently vortexed, to ensure they were 
in suspension, prior to inserting into the flow cytometer.  The percentage 
of viable, apoptotic and necrotic cells was measured with the use of argon 
laser excitation at 488 nm. 
 
 
2.11 DNA FRAGMENTATION 
 
2.11.1 DNA EXTRACTION 
 
Three different extraction protocols with different lysis buffers (Table 2.3) 
were used to extract DNA.  The sources of all the chemicals and 
equipment used are listed in Appendix 1.11.  The composition and 
preparation of the solutions and buffers are described in Appendix 2.11.  
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Cells (1 x 106) were seeded in 30 mm Nunc petri dishes.  After treatment 
with various agents (Chapter 2.2), the cells were washed with cold PBS as 
previously described (Chapter 2.1.2). 
 
For Protocol 1, DNA lysis buffer 1 (100 µl) was added to the cells, which 
were then incubated at 37°C for 30 min.  Proteinase K (50 µl of a 10 
mg/ml solution) was added to the samples and incubated for a further 30 
min at 37°C.  An equal volume of gel loading buffer was added to stop the 
reaction.  The samples were stored at -70°C until required. 
 
For Protocol 2, DNA lysis buffer 2 (500 µl) was added to the cells and 
incubated for 30 min at 37°C.  One-tenth volume (50 µl) of 3 M sodium 
acetate and two volumes of ice cold ethanol (1000 µl) were added.  This 
was incubated at -70°C for 20 min.  The samples were centrifuged using 
an Eppendorff micro-centrifuge for 5 min at 13 000 rpm.  The 
supernatants were discarded and the pellets washed twice in 70% 
ethanol.  The pellets were air dried, then resuspended in 100 µl TE buffer.  
The samples were stored at -70°C until required. 
 
For Protocol 3, the cells were placed directly in Eppendorff tubes labelled 
‘B’ (bottom).  The samples were centrifuged in a micro-centrifuge at 3 000 
rpm for 10 min (4°C).  The supernatants were transferred to new 
Eppendorff tubes labelled ‘S’ (supernatant).  TTE buffer (500 µl) was 
added to the pellets in the tubes labelled B, and this was vigorously 
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vortexed until the pellet was resuspended.  The B tubes were centrifuged 
at 10 000 rpm for 10 min (4°C).  The supernatants were transferred to new 
Eppendorff tubes labelled ‘T’ (top), and the pellets in B were gently 
resuspended in 500 µl TTE buffer.  Tubes S, B and T had 100 µl of ice 
cold 5 M NaCl added and they were vigorously vortexed for 10 seconds.  
Ice cold isopropanol (700 µl) was added to each tube and they were 
vortexed again.  Precipitation of the DNA was allowed to occur by 
incubating the tube at 20°C overnight.  The DNA was recovered by 
centrifuging in a microcentrifuge at 4°C (10 000 rpm) for 10 min.  The 
supernatants were removed and the pellets washed in 500 µl ice cold 70% 
ethanol.  The samples were spun down in a micro-centrifuge for 10 min at 
10 000 rpm (4°C).  The supernatants were discarded and the excess fluid 
removed by inverting the tubes on absorbent paper towel for 30 min.  The 
DNA pellets were air dried for 3 hours before they were resuspended in 50 
µl TE buffer and incubated at 37°C for 48 hours.  Loading buffer (50 µl) 
was added to each sample, which was then heated in a heating block at 
65°C for 10 min.  The samples were stored at -70°C until required.  
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Table 2.3 Composition of lysis buffers used in DNA extraction from HL-
60 cells 
 
Lysis Buffer Composition 
Protocol 1 1 M Tris- HCl (pH 7.4), 0.5 M EDTA (pH 7.5), 1 % RNAse- A, 0.25% NP-40 
Protocol 2 
1 M Tris- HCl (pH 7.4), 0.5 M EDTA (pH 7.5),  
1 % RNAse- A, 0.25% NP-40 
Protocol 3 
(TTE Buffer) 
TE buffer (pH 7.4), 0.2 % Triton-X 
 
2.11.2 DETERMINATION OF DNA CONCENTRATION 
 
The DNA was diluted 1:100 in TE buffer. The absorbance was measured 
using a spectrophotometer at two wavelengths, firstly 260 nm and 
secondly at 280 nm.  Nucleic acids have optimal absorbance at 260 nm, 
whereas proteins absorb light optimally at 280 nm.  The 260/280 ratio was 
determined.  A low ratio indicated that high concentrations of proteins 
were present in the sample, the higher the ratio the purer the DNA.  An 
absorbance of 1 at wavelength 260 nm indicates a DNA concentration of 
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50 ng/µl. The calculation for the determination of DNA concentration is as 
follows: 
 
DNA Concentration = Absorbance X 50 X Dilution factor 
 
2.11.3 VISUALISATION OF DNA FRAGMENTATION 
 
Agarose (1 g) was dissolved in 100 ml 1X TEA buffer by boiling.  The 
solution was allowed to cool until it was approximately 60°C.  Ethidium 
bromide (3 µl) was added and the solution mixed well.  Ethidium bromide 
intercalates with nucleic acids and fluoresces under ultra violet (UV) light.  
The solution was poured into the casting chamber, the combs inserted.  
The gel was allowed to set for 20 min. 
 
Once the gel had set the chambers of the running system were filled with 
1X TEA buffer.  Each sample (10 µl) (protocol 1 and 2) were mixed with 
approximately 3 µl loading buffer (protocol 3 already mixed with loading 
buffer) and placed in the wells.  The samples were run at 60 V for 1 hour.  
The gels were viewed using the Syngene gel viewing system.   
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2.12 THE LACTATE DEHYDROGENASE (LDH) ASSAY 
 
Apoptosis ‘packages’ the cellular contents into small vesicles, whereas 
necrosis is characterized by the disruption and loss of membrane integrity.  
As a consequence, the cellular contents including LDH are released into 
the medium, allowing the LDH activity to be measured and the degree of 
necrosis determined.  This study, in conjunction with the other apoptosis 
detection techniques, was used to confirm cell death due to apoptosis and 
not necrosis.  The LDH activity in culture medium was determined at RT 
by measuring the decrease in NADH absorbance at 340 nm with time. 
    
Pyruvate + NADH → Lactate + NAD   
 
The suppliers of the reagents and equipment used are listed in Appendix 
1.12, and the preparation of the buffers is described in Appendix 2.12.  
The medium from samples prepared for DNA fragmentation and flow 
cytometry assays were collected and stored at -70°C until analysis.  All 
reagents for this assay were freshly prepared prior to the assay and 
placed on ice to prevent any enzymatic degradation.  The reaction was 
performed by placing LDH buffer in a quartz curvette (1 cm) along with 87 
mM monosodium pyruvate and 4.5 mM NADH (Final volume = 2.8 ml).  
Sample (200 µl) was added to the curvette, which was mixed by inverting 
twice.  The LDH activity was measured by monitoring the decrease in 
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NADH absorbance at 340 nm with time using a Perkin-Elmer 
spectrophotometer equipped with a chart recorder.  The reaction was 
allowed to take place at RT at a chart speed of 40 mm/min.  The LDH 
activity was calculated from the slopes of the chart recordings and 
expressed as nmoles NADH converted/min.  The negative control had 
medium not exposed to cells added to the curvette, whereas the positive 
control had 0.1 µg LDH added to the LDH buffer, pyruvate and NADH. 
 
Activity was calculated from the chart readings and expressed as µmoles 
NADH converted/min.  The absorbance of 1 mmol of NADH is 6.22, 
therefore the following calculation was used to calculate µmole NADH 
converted/min: 
   
LDH Activity = ∆Absorbance/time 
                          Σ 
       Where Σ = 6.22 
 
 
2.13 EXTRACTION, QUANTIFICATION AND ANALYSIS OF        
RNA 
 
Total cellular RNA is susceptible to degradation by Ribonucleases 
(RNases), therefore all work surfaces were sterilised with 10% bleach and 
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70% ethanol prior to and after use.  All equipment and tips were 
autoclaved and solutions were made up with Diethyl Pyrocarbonate 
(DEPC) treated water.  The suppliers of all chemicals, and equipment 
used are listed in Appendix 1.13.  Buffers and reagents used for the RNA 
work were prepared according to the recipes described in Appendix 2.13. 
 
2.13.1  RNA EXTRACTION WITH TRI-REAGENT 
 
Cells (5 x 106) cells were seeded in 30 mm Nunc petri dishes, and 
stimulated with various agents (Chapter 2.2) according to the experimental 
conditions.  After stimulation, the cells were centrifuged at 1500 rpm for 10 
minutes.  The medium was discarded and 1 ml of Tri-Reagent was 
added to the pellet.  Aspirating several times with a pipette lysed the cells, 
which were then transferred to an Eppendorff tube.  If necessary this cell 
suspension can be stored at -70°C for up to a month.  The samples were 
centrifuged in an Eppendorff centrifuge at 12 000 rpm for 10 min at 4°C.  
The supernatants were transferred to a clean Eppendorff and allowed to 
stand at RT for 10min, before adding 200 µl chloroform.  The tubes were 
vortexed for 15 sec and left to stand at RT for 10 min.  The samples were 
centrifuged at 12 000 rpm at 4°C for 10 min which resulted in the 
development of 3 layers.  The bottom phase was red and contained 
protein, the thin middle layer was white and consisted of DNA and the top 
phase, containing the RNA, was colourless (aqueous).  The upper layer 
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was transferred to a new Eppendorff, care was taken not to touch the 
interphase with the pipette tip.  Isopropanol (500 µl) was added to each 
sample, which was then vortexed and allowed to stand for 10 min at RT.  
A tiny RNA pellet was obtained after the tubes were centrifuged at 12 000 
rpm at 4°C for 10 min.  The supernatant was discarded and the pellet was 
dried by inverting the tube for several minutes on absorbent paper.  The 
RNA pellet was washed by adding 1 ml 75% ethanol, briefly vortexing, and 
centrifuging at 4°C for 10min at 12 000 rpm.  The ethanol was discarded 
and the pellets were allowed to air-dry until they become translucent.  The 
RNA was resuspended in 20 µl DEPC water by aspiration, and heated to 
55°C for 10 min.  The extracted RNA was stored until required at -70°C.      
 
2.13.2   TOTAL CELLULAR RNA QUANTIFICATION 
 
The RNA was diluted 1:250 in DEPC water. The absorbance was 
measured using a spectrophotometer at two wavelengths, firstly 260 nm 
and secondly at 280 nm.  Nucleic acids have optimal absorbance at 260 
nm, whereas proteins absorb light optimally at 280 nm.  The 260/280 ratio 
was determined.  A low ratio indicated that high concentrations of proteins 
were present in the sample.  Ratios of 1.8 or higher were considered pure 
enough for further use.  An absorbance of 1 at wavelength 260 nm 
indicates an RNA concentration of 40 ng/µl.  RNA concentration is 
calculated as follows: 
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RNA concentration (µg/ml) = Absorbance X 40 X Dilution factor  
          0.001 
 
2.13.3   DETERMINATION OF RNA INTEGRITY   
 
RNA is extremely susceptible to degradation from both endogenous and 
exogenous origins.  The integrity of the RNA was therefore evaluated 
using denaturing agarose gel electrophoresis.  Total cellular RNA run on a 
denaturing agarose gel separated into three distinct bands.  Each one 
represents a major RNA species produced in the cells, namely, the 28S, 
18S and 5S ribosomal RNA (rRNA).  Degraded RNA appeared as a 
smear. 
 
Agarose (0.5 g) was dissolved in 50 ml of 1X MOPS (pH 5.5 –7.0) solution 
by boiling.  The solution was allowed to cool until it was approximately 
60°C, before formamide (denaturant) and ethidium bromide were added. 
Ethidium bromide intercalates with nucleic acids and fluoresces under 
ultra violet (UV) light.  The solution was poured into the casting chamber, 
the combs inserted.  The gel was allowed to set for 20 min.    
 
Total cellular RNA (10 µg) was added to 15 µl RNA sample buffer.  The 
samples were denatured by heating at 65°C for 10 minutes, before they 
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were loaded onto the gel.  The gels were run in a 1X MOPS buffer 
containing ethidium bromide at 65 V (constant current) for approximately 1 
hour at RT.  The RNA was visualised using the Syngene gel viewing 
system   
 
 
2.14  REVERSE TRANSCRIPTION-POLYMERASE CHAIN 
REACTION ANALYSIS  
 
Reverse transcription-polymerase chain reaction (RT-PCR) technique 
allows the semi-quantitative analysis of gene expression (transcription of 
specific mRNA species) within the cell.  The total cellular RNA is 
transcribed into cDNA using reverse transcription.  This is followed by the 
amplification of a specific cDNA region to detectable levels using 
polymerase chain reaction (PCR). 
 
The suppliers for the kits, primers and other chemicals used are listed in 
Appendix 1.14.  The exact details for the preparation of the buffers and 
reagents for the RT- and multiplex- PCR are described in Appendix 2.14.  
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2.14.1   REVERSE TRANSCRIPTION 
 
Reverse transcription  was performed using the Promega cDNA synthesis 
kit.    A master mix was prepared containing 1X Reverse Transcription 
Buffer, 1 mM of each of the four dNTPs, 5 mM MgCl2, 20 U RNase 
Inhibitor, 15-20 U AMV Reverse Transcriptase and 0.5 µg Oligo (dT)15 
Primer, which binds to the poly A tails of the RNA.  Master mix (10.1 µl) 
was added to 1 µg of RNA in an Eppendorff, and was made up to a final 
volume of 20 µl with nuclease free water.  A blank sample was included in 
each reverse transcription run, and had the total cellular RNA solution 
replaced with nuclease free water.  The reverse transcription was 
performed in the Hybaid Touchdown Thermocycler as follows; 45 min at 
42°C, 5 min at 95°C and finally at 4°C for 5 min.  The cDNA was stored at 
-70°C until PCR analysis was performed.    
 
2.14.2   MULTIPLEX PCR 
 
The sequence of AKT1 was obtained from the Gene Bank, Accession 
number NM_005163.  The two primer sequences used were obtained 
from Okano and colleagues (2000) and are designed in less conserved 5’ 
or 3’ non-coding regions to avoid any potential cross reactivity among the 
AKT isoforms.  The resulting forward and reverse primers (Table 2.4 and 
Fig. 2.3) resulted in the amplification of a 383 bp AKT1 product.  The 
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internal standard used for the semi-quantitative analysis of AKT1 was the 
housekeeping gene GAP-DH which is a 587 bp product.  
 
Table 2.4 The oligonucleotide primer sequences for AKT1 and GAP-               
DH 
mRNA Product Size                      Primer Sequence 
AKT1 383 bp Forward 5’ GCTGGACGATAGCTTGGA 3’ 
  Reverse 3’ CATGACAGATAGCTGGTG 5’ 
GAP-DH 587 bp Forward 5’ CCCTTCATTGACCTCAACTACATG 3’ 
  Reverse 3’ GACTTGCCCTTCGAGTGACCGTAC 5’ 
 
 
Figure 2.3 The sequence for the Human AKT1 gene and primer 
annealing positions.  The red text and arrow indicates the 
forward primer and the blue arrow and text indicates the 
reverse primer.  
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The PCR was performed using the Roche PCR Core Kit.  Prior to 
performing the PCR, the cDNA was diluted with 80 µl of nuclease free 
water. The cDNA (10 µl) was added to a pre-prepared master mix (14 µl) 
containing 0.4 µM and 0.05 µM of each of the AKT1 and GAP-DH primers 
respectively, 1X PCR Reaction Buffer with 1.5 mM MgCl2, 0.2 mM dNTPs 
and 2.5 U Taq polymerase, made up to a final volume of 50 µl with 
nuclease free water.  The PCR reaction mixture was overlaid with mineral 
oil to prevent evaporation.  Three controls were also prepared.  The first 
had the cDNA replaced with nuclease-free water to ensure that no 
contamination was present in the PCR master mix.  The second and third 
had only one set of primers added to each.  This was done to ensure that 
the amplification of the two products did not interfere with each other. 
 
The PCR was performed using a Hybaid Touchdown Thermocycler.  The 
cDNA was denatured at 94°C for 1 min, and then the primers were 
annealed at 55°C for 1 min.  Extension occurred at 72°C for 1 min.  This 
was repeated for 30 cycles, and then held at 4°C until the samples were 
retrieved.  The PCR products were stored at 4°C until subjected to 
electrophoresis. 
 
Agarose (2 g) was dissolved in 100 ml 1X TEA buffer by boiling.  The 
solution was allowed to cool until it was approximately 60°C.  Ethidium 
bromide (3 µl) was added to the solution and mixed well.  The solution 
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was poured into the casting chamber and the combs inserted.  The gel 
was allowed to set for 20 min. 
 
The chambers of the running system were filled with 1X TEA buffer.  Each 
sample (10 µl) were mixed with approximately 3 µl bromophenol blue 
loading buffer and placed in the wells.  The chamber was closed and the 
samples run at 65 V for 1 hour.  The PCR product was viewed using the 
Syngene gel viewing system.  The size of the product was determined by 
comparing its size relative to that of the 100 bp DNA Molecular Weight 
Marker.  
 
 
2.15 ENDONUCLEASE RESTRICTION ANALYSIS OF AKT1 
PCR PRODUCT 
 
The suppliers of the restriction enzymes and their buffers are listed in 
Appendix 1.15. 
 
To confirm that the amplified product was the correct sequence, a PCR 
control sample that was amplified with just the AKT1 primers was 
subjected to restriction analysis.  Three different restriction enzymes were 
used, XhoI, AvaI and HaeIII.  The cleavage sites for these enzymes were 
obtained from Restriction Mapper (www.restrictionmapper.org), and the 
cleavage positions are shown in Table 2.5 and Figure 2.4.  
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Each enzyme is supplied with its own 10X reaction buffer (Buffer M, H and 
B for XhoI, AvaI and HaeIII respectively).  The preparation of the 
restriction enzyme master mixes are described in Appendix 2.15.  PCR 
product (6µl) was added to 14 µl of the master mix in an Eppendorff tube, 
making a final volume of 20 µl.  The samples were incubated at 37°C for 
24 hrs and the resulting products were run on a 2% agarose gel as 
previously described.  
 
Table 2.5 The list of recognition sites and resultant fragments obtained 
for the three restriction enzymes used 
 
Restriction Enzyme Recognition Site Cleavage Sites 
Resulting Fragment 
Sizes 
AvaI CYCGRG 1717, 1750 33, 70, 279 
HaeIII GGCC 1680, 1871, 1951 33, 78,  80, 191 
XhoI CTCGAG 1750 103, 279 
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Figure 2.3 The sequence for the Human AKT1 gene and the cleavage 
sites of the restriction enzymes.  The blue arrow heads 
indicate the cleavage sites for Ava I, the green arrow heads 
indicate the cleavage sites for Hae III and the red arrow 
head indicates the cleavage site for Xho I. 
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CHAPTER 3 
 
RESULTS 
 
3.1 GROWTH/CYTOXICITY ASSAY 
 
3.1.1 GROWTH ASSAY 
 
Cells (50 000) were treated with 25 µM LY294002 for 1 hour prior to the 
addition of the different concentrations of PDGF (in triplicate). Figure 3.1 is 
the graphical representation of the mean % growth for the four 
experiments, and shows a decrease in the mean % growth when 25 µM 
LY294002 was added.  
 
The results obtained had large standard deviations hence were 
considered to be non-reproducible.  A preliminary study using the Trypan 
Blue exclusion test (results not shown) demonstrated a 10% increase in 
cell growth when the HL-60 cells were treated with the recommended 
(Sigma) PDGF concentration of 50 ng/ml.  Hence, the recommended 
PDGF concentration (50 ng/ml) was used in the remainder of the 
experiments, as was the recommended concentration of LY294002 (25 
µM). 
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Figure 3.1 A graphical representation of the mean and standard 
deviation of the % growth for four experiments (in triplicate) 
of 50 000 HL-60 cells treated with various concentrations of 
PDGF and 25 µM LY294002 for 48 hours 
 
3.1.2 CYTOTOXICITY ASSAY 
 
Cells (50 000) were treated with 25 µM LY294002 for 1 hour prior to the 
addition of the different concentrations of etoposide for 48 hours (in 
triplicate). Figure 3.2 is a graphical representation of the mean % survival 
of the three experiments, and indicates that the addition of 25 µM 
LY294002 results in a slight increase in cell death. The experiment had 
low standard deviations and is therefore more reproducible. 
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A large amount of cell death occurred between 0 µg/ml and 20 µg/ml 
etoposide (Fig. 3.2), therefore three experiments (in triplicate) were 
conducted with a range of etoposide between 0 µg/ml and 10 µg/ml.  
Figure 3.3 indicates that the HL-60 cells continue to grow in 
concentrations of etoposide less than 0.1 µg/ml, but a large percentage of 
cells die when the concentration of etoposide is increased to 1 µg/ml.   
 
 
 
 
 
 
 
 
 
Figure 3.2 A graphical representation of the mean and standard 
deviation of the % survival for three experiments (in triplicate) 
of 50 000 HL-60 cells treated with various concentrations of 
etoposide and 25 µM LY294002 for 48 hours 
 
The recommended concentration (Sigma) of etoposide was 60 µg/ml, and 
was shown to cause cell death with this technique.  Etoposide was 
therefore used at a concentration of 60µg/ml for all further experimental 
procedures. 
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Figure 3.3 A graphical representation of the % survival three 
experiments (in triplicate) of 50 000 HL-60 cells treated with 
a concentration range of etoposide for 48 hours  
 
 
3.2 IMMUNOBLOTTING 
 
The first step in the immunoblotting assay was to determine which protein 
extraction buffer to use.  Protein was extracted from 20 x 106 HL-60 cells 
using the five extraction buffers described in Chapter 2.4 (results not 
shown).  The SDS-lysing buffer (Buffer C) gave high protein yields 
(Chapter 2.5) however the samples were very globular and difficult to load 
on the SDS-PAGE gels.  The protein also appeared as smears on the gels 
when stained with Coomassie Blue stain (Chapter 2.6).  Buffers A and B 
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gave very low protein yields and were therefore not used.  Protein 
extracted with Buffer D gave high protein yields, however when 
immunoblotted no Phospho-Akt was present.  This was probably due to 
phosphatase activity in the lysate, as no phosphatase inhibitors were 
present in the lysing buffer.   The Akt lysing buffer (Buffer E), containing 
phosphatase inhibitors, also had a high protein yield, and when the 
samples were immunoblotted the Phospho-Akt was present.  It was 
therefore decided to use the Akt lysing buffer to extract protein for the 
experimental procedures.        
 
A time trial was conducted (in triplicate) by adding 50 ng/ml PDGF to the 
HL-60 cells for 5, 10, 15, 30, 45 and 60 minutes.  The resultant blots 
indicated that optimal phosphorylation of Akt occurs at 15 and 30 minutes 
(results not shown).  Therefore, for the remaining experiments these time 
frames were used.  
 
Protein was extracted from HL-60 cells (20 x 106) stimulated with 25 µM 
LY294002 for 1 hour, prior to the addition of 50 ng/ml PDGF for 15 and 30 
minutes.  The protein (40 µg) was then run on a SDS-PAGE, western 
blotted and immunoblotted with Akt, Phospho-Akt, Phospho-IκB and 
Phospho-IKK antibodies.  The experiment was repeated several times and 
a representative of the resulting blots are shown in Figure 3.4.  In all 
experiments performed the blot of total Akt was used as a loading control. 
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Figure 3.4 A representation of the four immunoblots obtained from 40 
µg protein extracted from HL-60 cells (20 x 106) treated with 
25 µM LY294002 for 1 hour before 50 ng/ml PDGF was 
added for 15 and 30 min.  1 = Untreated Cells, Cells treated 
with: 2 = DMSO, 3 = HCl-BSA, 4 = LY294002, 5 = 15 min 
PDGF, 6 = 30 min PDGF, 7 = 15 min PDGF + LY294002 and 
8 = 30 min PDGF + LY294002. 
 
The changes in the intensity of the bands is difficult to detect with the 
naked eye, therefore they were scanned using the Genesnap Tools 
program.  The resulting band densities were plotted in Fig. 3.5. 
 
 
 
 
 
  87 
 
 
 
 
 
 
 
 
 
Figure 3.5 The mean protein band intensities from three experiments of 
Akt, Phospho-Akt, Phospho-IκB and Phospho-IKK. 
 
Figure 3.5 shows that when the cells are stimulated with 50 ng/ml PDGF 
there is an increase in Akt phosphorylation, however when 25 µM 
LY294002 is added 1 hour prior to the addition of PDGF there is a 
decrease in phosphorylation.  This decrease is more apparent with the 30 
minute period, however the significance is dubious.  A high amount of IκB 
phosphorylation occurs when the cells are treated with LY294002 for 1 
hour, as well as when they are stimulated with PDGF for 30 minutes.  
Stimulation of cells for 15 minutes with PDGF seems to have no marked 
affect on IκB phosphorylation, however a slight decrease in IκB 
phosphorylation is shown after the cells have been treated with LY294002 
and PDGF for 30 minutes.  IKK phosphorylation increases dramatically 
with all the treatments (Fig. 3.5). 
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3.3 ACRIDINE ORANGE-ETHIDIUM BROMIDE ASSAY 
 
The acridine orange-ethidium bromide assay is a morphological assay, 
which allows the different stages of cell death to be identified.  The uptake 
of the two fluorescent dyes by the cells in these different stages is 
described in Chapter 2.11.  Figure 3.6 is a schematic representation and 
Figure 3.7 is an enlarged photographic representation of the different 
stages of cell death, and assists in the interpretation of the photographs.  
 
 
Figure 3.6 A schematic illustration of the different stages of apoptosis 
and of necrosis, showing the differential uptake of acridine 
orange and ethidium bromide. 
 
The assay was repeated three times and the images in this section are a 
representation of the results obtained.  For all the experiments 1 x 106 HL-
60 cells were grown in 15 mm petri dishes for 48 hours before being 
viewed and photographed at 400X magnification with the confocal 
microscope.   
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Figure 3.7 An enlarged photographic representation of HL-60 cells in 
the different stages of apoptosis and necrosis, showing the 
differential uptake of acridine orange and ethidium bromide.  
Panel A represents normal cells, B is a cell undergoing early 
apoptosis with 1 indicating the characteristic ‘horse shoe’ 
shape of the condensed nucleus and 2 showing membrane 
blebbing.  Panel C represents a cell undergoing late 
apoptosis with 3 indicating the very granular cytoplasm.  
Panel D is a necrotic cell. 
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A number of control samples were prepared and are described by Figures 
3.8-11.  Figure 3.8 is HL-60 cells that have been growing under normal 
conditions; the majority of cells in the field are healthy (H), as they appear 
green with a non-granular cytoplasm.  Normal cell death does occur under 
these conditions and is represented by the late apoptotic cells (LA).  A 
large orange necrotic cell (N) is also present in this field of view.  DMSO is 
the vehicle used for etoposide, cyclohexamide and LY294002, and it is 
therefore essential to ensure that the stimulants and not the vehicle are 
causing cell death.  Figure 3.9 is HL-60 cells stimulated with DMSO for 48 
hours, and the cells appear very similar to those in Figure 3.8.  LY294002 
(25 µM) was added to the HL-60 cells in Figure 3.10; the cells appear to 
be healthy (H), with a small proportion entering early apoptosis (EA) 
evident by the presence of membrane blebbing and nuclear condensation.  
The membrane blebbing is not apparent in the photographs, but was 
present when the cells were viewed under the microscope.   The necrosis 
control (Fig. 3.11) has several large orange necrotic cells (N) present as 
well as cells undergoing apoptosis (EA), however no normal cells are 
visible.  The experimental samples of the HL-60 cells treated with various 
combinations of apoptosis inducing agents and the PI3-kinase pathway 
inhibitor LY294002 are shown in Figures 3.12-17.  Etoposide (60 µg/ml) 
was added to the cells in Figure 3.12 and although a few healthy cells (H) 
are present, the majority of cells have entered early (EA) and late (LA) 
apoptosis.  The HL-60 cells Figure 3.13 were treated with both 60 µg/ml 
etoposide and 25 µM LY294002.  No normal cells are present as most of 
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the cells are in early apoptosis (EA) and the remainder have entered late 
apoptosis (LA).  Cyclohexamide (3 µg/ml) has been reported to be an 
apoptosis control for HL-60 cells, however, Figure 3.14 indicates 
otherwise as most of the cells are healthy (H), with a few exhibiting 
nuclear condensation and membrane blebbing (visible under microscope 
but lost in reproduction) indicative of early (EA) and late (LA) apoptosis.  
The addition of both 3 µg/ml cyclohexamide and 25 µM LY294002 (Fig. 
3.15) also proved to have no extensive effect, as most of the cells are 
healthy (H) with a small number exhibiting early apoptosis (EA).  HL-60 
cells treated with both 60 µg/ml etoposide and 3 µg/ml cyclohexamide 
(Fig. 3.16) exhibit a large proportion of cells in early apoptosis (EA) as the 
cells have nuclear condensation and characteristic horseshoe shaped 
nuclei, membrane blebbing (visible under microscope but lost in 
reproduction) is also evident.  The remaining small proportion of cells are 
in late apoptosis (LA) as the cells appear either green or orange with large 
orange granules (nuclear material) present in the cytoplasm.  In Figure 
3.17 the cells have been treated with all three stimulants, 60 µg/ml 
etoposide, 3 µg/ml cyclohexamide and 25 µM LY294002.  The proportion 
of cells in early (EA) and late (LA) apoptosis appears to be equal, and no 
healthy cells are present.       
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Figure 3.8 HL-60 cells (1 x106) grown under normal conditions for 48 
hours.  H = healthy cells, N = necrotic cells, LA = late 
apoptosis 
Figure 3.9 HL-60 cells (1 x106) stimulated with DMSO, the vehicle for 
etoposide, cyclohexamide and LY294002 for 48 hours.  H= 
healthy cells, N = necrotic cells, LA = late apoptosis 
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Figure 3.10 HL-60 cells (1 x 106) stimulated with the PI3-kinase pathway 
inhibitor LY294002 (25µM) for 48 hours.  H = healthy cells, EA 
= early apoptosis 
Figure 3.11 HL-60 cells (1 x 106) subjected to freeze-thawing to give a 
necrosis positive control.  N = necrotic cells, EA = early 
apoptosis 
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Figure 3.12 HL-60 cells (1 x 106) stimulated with 60 µg/ml etoposide for 48 
hours.  H = healthy cells, EA = early apoptosis, LA = late 
apoptosis 
Figure 3.13 HL-60 cells (1 x 106) stimulated with 25µM LY294002 for 1 hour 
before 60 µg/ml etoposide was added, then incubated for a further 48 
hours.  EA = early apoptosis, LA = late apoptosis 
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Figure 3.14 HL-60 cells (1 x 106) treated with 3 µg/ml cyclohexamide for 
48 hours.  H = healthy cells, EA = early apoptosis, LA = late 
apoptosis 
Figure 3.15 HL-60 cells (1 x 106) treated with 25 µM LY294002 for 1 hour prior 
to the addition of 3 µg/ml cyclohexamide and then incubated for a 
further 48 hours.  H = healthy cells, EA = early apoptosis 
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Figure 3.16 HL-60 cells (1 x 106) stimulated with 60 µg/ml etoposide and 
3 µg/ml cyclohexamide for 48 hours.  EA = early apoptosis, 
LA = late apoptosis 
Figure 3.17 HL-60 cells (1 x 106) incubated with 25 µM LY294002 (one hour) 
before the addition of 60 µg/ml etoposide and 3 µg/ml cyclohexamide 
for 48 hours.  EA = early apoptosis, LA = Late apoptosis 
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3.4 FLOW CYTOMETRY 
 
Flow cytometry was performed (3 experiments) on 3 x 103 HL-60 cells 
treated with 60 µg/ml etoposide, 3 µg/ml cyclohexamide and 25 µM 
LY294002 for 48 hours.  Figure 3.18 (A-J) are representative dot plots that 
were obtained from these samples when they were stained with YO-PRO-
1 and propidium iodide.  Each of these dot plots contains four quadrants 
labelled 1-4 that help to separate the different cell populations.  The 
different colours can also differentiate the cell populations.  The black 
indicates viable cells, the green indicates apoptotic cells and red indicates 
necrotic cells.  The dot plots also appear to have a characteristic ‘scorpion 
tail’ pattern.  Quadrant 1 contains cellular debris and the necrotic cells are 
present in quadrant 2.  Quadrant 3 consists of normal viable cells and 
quadrant 4 contains the apoptotic cells.  The percent of each population 
was calculated by COULTIER(R) EPICS(R) program and were plotted in 
Figure 3.19. 
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Figure 3.18 Representative dot plots obtained from 3 x 105 HL-60 cells passed through the Beckman-Coultier Flow cytometer 
after being stained with YO-PRO-1 and propidium iodide.  The cells were treated with 25 µM LY294002 for 1 hour 
prior to the addition of 60 µg/ml etoposide and 3 µg/ml cyclohexamide for 48 hours.  A = Untreated cells (Blank), 
Cells treated with: B = DMSO, C = LY294002, D = Necrotic Control, E = etoposide, F = etoposide + LY294002, G = 
cyclohexamide, H = cyclohexamide + LY294002, I = etoposide + cyclohexamide and J = etoposide + cyclohexamide 
+ LY294002. 
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Figure 3.18 A-D are the control samples, where A is HL-60 cells grown 
under normal conditions, B are the cells treated with the vehicle DMSO, C 
are cells stimulated with 25 µM LY294002 and D is the necrotic control.  
Figure 3.18 A-C and Figure 3.19 indicate that the majority of the cell 
populations are normal (96.45%, 96.23% and 93.3% respectively), 
however negligible apoptosis (1.36%, 1.52% and 2.19%) and necrosis 
(0.96%, 0.88% and 1.84%) do occur.  In the necrotic control the majority 
of the cells appear to be undergoing necrosis (90.37%), and a large 
amount of cell debris is present (8.69%) Fig. 3.18 D & Fig. 3.19). 
 
A large proportion of cells treated with 60 µg/ml etoposide undergo 
apoptosis (45.36%), however when they are treated with 25 µM 294002 
for 1 hour prior to the addition of etoposide, the number of cells 
undergoing apoptosis is increased to 53.08% (Fig. 3.18 E-F & Fig. 3.19).  
Cyclohexamide (3 µg/ml) causes a small amount of apoptosis (1.97%), 
which is increased when 25 µM LY294002 is added (6.91%) (Fig. 3.18 G-
H & Fig. 3.19).  The stimulation of cells with etoposide and cyclohexamide 
results in 37.45% apoptosis, but when LY294002 is added it is increased 
to 52.72% (Fig. 3.18 I-J & Fig. 3.19).   
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Figure 3.19 The mean and standard deviation of the percentage of the 
HL-60 cell population from 3 experiments that are viable, 
apoptotic or necrotic after pre-treatment with 25 µM 
LY294002 for 1 hour prior to the addition of 60 µg/ml 
etoposide or 3 µg/ml cyclohexamide for 48 hours.  
 
 
3.5 DNA FRAGMENTATION 
 
DNA fragmentation was performed on 1 x 106 HL-60 cells treated with 
combinations of 60 µg/ml etoposide, 3 µg/ml cyclohexamide and 25 µM 
LY294002 for both 48 and 72 hours.  This was repeated numerous times 
with several different techniques, however no DNA fragmentation was 
present.  Figure 3.20 A-C demonstrates the DNA obtained using Protocol 
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3 (Chapter 2.9.1).  The only DNA present on these gels appears as 
smears (Fig 3.20).  
 
 
 
Figure 3.20 DNA extracted from 1 x 106 HL-60 cells using Protocol 3.  
The 1% agarose gel A shows the ‘S’ fraction, B shows the ‘T’ 
fraction and C shows the ‘B’ fraction of the extraction after 48 
hours of stimulation.  Cells treated with: 1 = Normal 
conditions, 2 = DMSO, 3 = LY294002, 4 = etoposide, 5 = 
etoposide + LY294002, 6 = cyclohexamide, 7 = 
cyclohexamide + LY294002, 8 = etoposide + cyclohexamide, 
9 = etoposide + cyclohexamide + LY294002 and 10 = 
necrosis control.  
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3.6 THE LDH ASSAY 
 
The cytotoxicity assay indicated that a large amount of cell death occurred 
when the HL-60 cells were treated with 0.01 µg/ml – 10 µg/ml etoposide 
for 48 hours.  The LDH activity in the medium was therefore tested at this 
concentration range with the addition of 25 µM LY294002.  The medium of 
cells treated for 48 hours with the recommended and most commonly 
used concentration of 60 µg/ml etoposide was also tested. 
  
 
 
 
 
 
 
 
 
Figure 3.21 The mean and standard deviation of LDH activity (nmol/min) 
in culture medium of three experiments of HL-60 cells 
treated with a concentration range of etoposide and 25 µM 
LY294002. 
 
Figure 3.21 is the mean of the LDH activity for three experiments, a LDH 
positive control was also tested by adding 10 U of LDH to the reaction in 
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place of the test medium.  The LDH positive control (not represented on 
the graph) had an activity of 94.054 nmol/min, demonstrating that the 
assay was working.  The LDH activity in all the test samples were 
negligible, with most activities under 2 nmol/min.  The exception being the 
samples treated with 25 µM LY294002, 1µg/ml etoposide + LY294002 and 
10 µg/ml etoposide + LY294002.  The necrosis control, as expected, had 
the highest LDH activity of 15.5 nmol/min (Fig. 3.21). 
 
 
3.7 RNA ANALYSIS 
 
RNA was extracted from 5 x 106 HL-60 cells treated with 25 µM LY294002 
for 1 hour before 50 ng/ml PDGF was added for 15 and 30 minutes.  This 
was performed in triplicate and if the absorbance ratio (260 nm/280) nm 
was less than 1.8 the experiment was discarded and performed again.  
RNA was also extracted from cells treated with the combination of 25 µM 
LY294002 and 60 µg/ml etoposide for 4 hours.  It appeared that the 
addition of etoposide had a detrimental effect on the integrity of the RNA 
as the highest purity obtained was 1.5.  Nonetheless, RT-PCR was still 
performed in triplicate on these samples.   
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Figure 3.22 A 2% agarose gel showing 5 different RNA extractions.  The 
arrows indicate the three major RNA species (28S, 18S and 
5S). 
 
The quality of RNA was also checked using agarose gel electrophoresis, 
and any samples that did not exhibit three crisp bands were discarded.  
Figure 3.22 is a representative gel showing RNA extracted from 5 
samples.  All three major RNA species (28S, 18S and 5S) are present and 
there is no smearing of the bands.     
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3.8  REVERSE TRANSCRIPTION-POLYMERASE CHAIN      
REACTION ANALYSIS 
 
The RT-PCR was performed on 1 µg of RNA extracted from the samples 
(in triplicate) described in Chapter 2.7.  These were then subjected to 
multiplex PCR. 
 
3.8.1 RESTRICTION ENZYME ANALYSIS OF AKT PCR PRODUCT 
 
Three cDNA products were subjected to PCR with the Akt forward and 
reverse primers.  These PCR products were then digested with 3 
restriction enzymes (Ava I, Hae III and Xho I), and run on a 2% agarose 
gel.  The products obtained with each of the restriction enzymes, Xho I 
(103 bp and  279 bp), Ava I (33 bp, 70 bp and 279 bp) and Hae III (33 bp, 
78 bp, 80 bp and 191 bp) proved that the Akt primers were amplifying the 
correct product as is shown in Figure 3.23.  The 33 bp cDNA fragments 
are not visible on the gel as they are too small, and the 79 and 80 bp 
fragments obtained with the Hae III enzyme are difficult to differentiate 
due to the similarity in size (Fig 3.23).   
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Figure 3.23 A 2% agarose gel showing the Akt PCR product cut by the 
three restriction enzymes, Ava I, Hae III and Xho I.  Lanes 1, 
3 and 5 contain uncut control cDNA products, Lane 2 is the 
Xho I products, lane 4 is the Ava I products, lane 6 is the 
Hae III products and lane MW is the 100 bp molecular weight 
ladder. 
 
3.8.2 MULTIPLEX PCR OF HL-60 CELLS STIMULATED WITH PDGF 
 
The multiplex PCR gave two bands, the first was 587 bp (GAP-DH) and 
the second was 383 bp (Akt).  Figure 3.24 is a representative 2% agarose 
gel of HL-60 cells stimulated with 50 ng/ml PDGF and 25 µM LY294002.  
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The intensities of the bands were scanned using the Genesnap Tools 
program.  The GAP-DH band was used as a control band and the ratio is 
compared to Akt in Figure 3.24. 
 
 
 
Figure 3.24 A 2% agarose gel showing the multiplex PCR of RNA 
extracted from 1 x 106 HL-60 cells stimulated with 25 µM 
LY294002 for 1 hour prior to the addition of 50 ng/ml PDGF 
for two different time periods.  MW represents the 100 bp 
DNA ladder.  Lanes 1-4 are control samples; 1 = cells grown 
in 10% FCS, 2 = DMSO, 3 = HCl-BSA and 4 = 25 µM 
LY294002.  Lanes 5-8 are the test samples; 5 = PDGF (15 
min), 6 = PDGF (30 min), 7 = PDGF (15 min) + LY294002 
and 8 = PDGF (30 min) + LY294002.  Lanes 9-12 are once 
again control samples; 9 = The RT-PCR blank, 10 = the 
multiplex PCR blank, 11 = normal cells with the GAP-DH 
primers and 12 = normal cells with the Akt primers.    
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The band intensity of the two PCR products GAP-DH and Akt of the 10% 
FCS control are very similar and give a ratio of Akt/GAP-DH of 0.95.  The 
Akt/GAP-DH ratios were not significantly different in the samples treated 
with PDGF.  However the Akt band intensities and the ratio for the 
samples treated with 25 µM LY294002 were decreased in the presence 
and absence of PDGF, indicating a decrease in Akt mRNA expression 
when the PI3-kinase pathway is inhibited (Figs. 3.24 & 3.25). 
 
 
 
 
 
 
 
 
 
 
Figure 3.25 The mean and standard deviation of the ratio of Akt/GAP-DH 
showing the changes in the Akt mRNA expression obtained 
from 3 experiments when the HL-60 cells (1 x 106) were 
treated with 50 ng/ml PDGF for various time periods with the 
combination of 25 µM LY294002.  
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3.8.3 MULTIPLEX PCR OF CELLS TREATED WITH ETOPOSIDE 
 
Figure 3.26 is a representative gel of the multiplex PCR conducted on the 
RNA extracted from HL-60 cells treated for 4 hours with 60 µg/ml 
etoposide in addition to the treatment with 25 µM LY294002 for 1 hour (in 
triplicate).  The intensities of the bands were scanned using the Genesnap 
Tools program as previously described, and plotted as ratios in Figure 
3.27. 
 
 
The intensity of all of the Akt bands and Akt/GAP ratios were very low, 
however when the cells were treated with 25 µM LY294002 as well as with 
etoposide, the Akt bands were absent.  This was not the case with 
cyclohexamide and LY294002 (Figs 3.26 & 3.27). 
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Figure 3.26 A 2% agarose gel showing the multiplex PCR of RNA 
extracted from 1 x 106 HL-60 cells treated with 25 µM 
LY294002 1 hour prior to the addition of etoposide (60 
µg/ml) and cyclohexamide (3 µg/ml) for 4 hours.  MW 
represents the 100 bp DNA ladder.  Lanes 1-3 are control 
samples; cells treated with: 1 = normal conditions, 2 = 
DMSO and 3 = 25 µM LY294002.  Lanes 4-10 are test 
samples; cells treated with: 4 = etoposide, 5 = etoposide + 
LY294002, 6 = cyclohexamide, 7 = cyclohexamide + 
LY294002, 8 = etoposide + cyclohexamide, 9 = etoposide + 
cyclohexamide + LY294002 and 10 = Necrosis.  Lanes 11-
14 are once again control samples; 11 = the RT-PCR blank, 
12 = the multiplex PCR blank, 13 = normal cells with the 
GAP-DH primers and 14 = normal cells with the Akt primers.    
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Figure 3.27 The mean and standard deviation of the ratio of Akt/GAP-DH 
showing the changes in the Akt mRNA expression obtained 
from three experiments when the HL-60 cells (1 x 106) were 
treated with 60 µg/ml etoposide and 3µg/ml cyclohexamide 
for 4 hours with the combination of 25 µM LY294002.   
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CHAPTER 4 
 
DISCUSSION 
 
The role that the PI3-kinase pathway plays in oncogenesis has been well 
documented as many oncogenic downstream targets have been 
identified.  One of these targets, Akt, has also been implicated in cancer, 
however the part it plays is not entirely clear.  Many studies have been 
conducted in leukaemic cells to determine the effect that inhibiting the 
PI3-kinase/Akt pathway has on cytotoxic drug induced apoptosis.  One 
such study was performed by O’Gorman and co-workers (2000), who 
determined that HL-60 cells are more susceptible to drug-induced 
apoptosis if the PI3-kinase pathway is inhibited.  The PI3-kinase/Akt had 
been previously shown to mediate heterodimer interactions of BAD, a 
proapoptotic regulator, with Bcl-2 and Bcl-XL. On phosphorylation by Akt, 
BAD is sequestered in the cytoplasm by the 14-3-3 protein and its 
interactions with anti-apoptotic Bcl members is prevented, thus inhibiting 
apoptosis.  O’Gorman and colleagues (2000) found that inhibition of PI3-
kinase didn’t lead to BAD heterodimer formation with Bcl–X or Bcl-2
 
or the 
presence of non-phosphorylated BAD, suggesting that an alternative 
pathway is involved in the survival factor-mediated drug resistance in HL-
60 cells.  Other studies, including one conducted by Delhause and co-
workers (2000) revealed that an interaction between Akt and IKK exists in 
HL-60 cells.  This suggested that the pro-survival pathway responsible for 
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decreasing cytotoxic drug induced apoptosis in HL-60 cells is the IKK, IκB 
and NF-κB pathway. 
 
This study was designed to confirm the observations that inhibiting the 
PI3-kinase/Akt pathway led to increased cytotoxic drug induced apoptosis, 
made by O’Gorman and co-workers (2000), as well as to confirm that this 
pathway activates IKK and IκB as was elucidated by Delhause and 
colleagues (2000).   
 
The cytotoxic drug etoposide was used in this study and had been 
previously shown to cause apoptosis in HL-60 cells by O’Gorman and co-
workers (2000).  Their findings were confirmed in the present study by the 
cytotoxicity assay which revealed that cell death occurred at a 
concentration as little as 10 µg/ml etoposide, and cells treated with 60 
µg/ml etoposide had a 70% decrease in survival.  In the current study, the 
inhibition of the PI3-kinase pathway by the addition of 25 µM LY294002 
resulted in an approximately 10% increase in cell death, whereas 
O’Gorman and co-workers demonstrated an approximate 30% increase in 
cell death.  This indicates that the PI3-kinase pathway plays a small anti-
cell death role in HL-60 cells treated with cytotoxic drugs.  The 
disadvantage of this method was that it did not demonstrate whether the 
decrease in cell number was due to apoptosis or necrosis, and further 
experimentation was required to determine the mechanism of cell death.  
Therefore four other techniques were used to confirm apoptosis, the 
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acridine orange-ethidium bromide assay, flow cytometry, DNA 
fragmentation and the LDH activity assay.  The flow cytometry assay was 
the only quantitative assay performed, whereas the acridine orange-
ethidium bromide assay showed the changes in cell morphology.  The 
DNA fragmentation assay was used to demonstrate internucleosomal 
digestion of DNA indicative of apoptosis, and the LDH assay was used to 
confirm that necrosis had not occurred.  
 
As was previously described, the morphology of cells undergoing 
apoptosis and necrosis is substantially different.  The acridine orange-
ethidium bromide assay was used to identify the morphological changes in 
the HL-60 cells treated with etoposide, cyclohexamide and LY294002.  
The assay was described in T47D and HEK293 cell lines by Gibson and 
colleagues (1999).  They used the technique to determine the percentage 
of apoptotic cells after adding anti-Fas antibody for several time periods.  
Unlike these authors, it was decided that the technique in this case was 
only usable as a qualitative and not a quantitative assay for two reasons.  
Firstly, large numbers of cells (2 x 106) need to be present in each field for 
the results to have any statistical relevance.  Secondly, the classification 
of the cells into the different categories (H, EA, LA and N) is at the 
discretion of the individual doing the analysis. 
 
The flow cytometry assay was used to quantitatively confirm the results 
obtained in the acridine orange-ethidium bromide assay. This is a very 
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sensitive technique as viable cells are not stained by either dye, apoptotic 
cells bind YO-PRO-1 and propidium iodide enters necrotic cells staining 
the DNA.  Studies by Dylacht and co-workers in 1999 and 2000 described 
the use of propidium iodide and FITC to determine the percentage 
apoptosis of HL-60 cells treated with radiation, hyperthermia and 
etoposide.  This technique used by Dylacht and co-workers (1999 & 2000) 
is highly sensitive, as they incubated the cells with a monoclonal antibody 
against human lamin B, an apoptosis marker.  This was then incubated 
with a secondary antibody that was conjugated with FITC, and the cells 
were stained with propidium iodide (Dylacht et al, 1999; Dylacht et al, 
2000).  They obtained the same characteristic ‘scorpion tail’ in apoptotic 
samples as was found in this study, however they had a very high 
percentage of apoptotic cells (79%) when treated with 12 µg/ml etoposide 
for 6 hours.   
 
In the present study both the confocal microscopy and flow cytometry 
assays confirmed that etoposide treated HL-60 cells have a decrease in 
cell survival due to apoptosis, however the flow cytometry allowed the cell 
death to be quantitatively differentiated into apoptosis and necrosis.  
Normal cell populations were shown to contain a large percentage of 
normal cells, with a few cells undergoing apoptosis and necrosis.  
Approximately 45% of the cells treated with 60 µg/ml etoposide for 48 
hours were undergoing apoptosis and this is increased to 53% when they 
were pre-treated with 25 µM LY294002, confirming the findings of 
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O’Gorman and co-workers (2000) (70% and 100% respectively), but in 
this study there were lower levels of apoptosis.  O’Gorman and colleagues 
(2000) also used flow cytometry to obtain these results, however they 
detected apoptosis by measuring the amount of light scatter and necrosis 
by the amount of propidium iodide included into the cell.  Propidium iodide 
can only enter the cell once the membrane has been compromised as is 
the case with necrosis (Vermes et al, 1997).  Therefore the technique 
used by O’Gorman and co-workers (2000) is less sensitive than the 
technique used in this study, as both light scatter and the uptake of two 
dyes were analysed.  
 
The LDH activity of the medium surrounding the treated cells proved to be 
negligible, and the numbers of necrotic cells were low implying that little or 
no necrosis was occurring.  Cyclohexamide was described as an apoptotic 
positive control (3 µg/ml) in HL-60 cells by Sigma, and was shown to 
cause apoptosis (20 µg/ml) in Human Jurkat and CEM C7 cell lines by 
Tang and co-workers (1999).  Therefore 3 µg/ml cyclohexamide was used 
as a positive control in this study.  The results were opposite to what was 
expected, as the majority of the cells in the field appeared healthy.  This 
was also the case when 25 µM LY294002 was added prior to the addition 
of the cyclohexamide.  These findings were confirmed with flow cytometry 
as the addition of cyclohexamide resulted in 1.97% apoptosis, which was 
increased to 6.91% when LY294002 was added.   The cyclohexamide 
 117 
used had passed its expiry date, and it is suspected that it was no longer 
active. 
 
As previously mentioned DNA fragmentation is indicative of apoptosis and 
was attempted to confirm the results obtained with the experiments 
described above in the present study.  This technique has been formerly 
used to demonstrate apoptosis in HL-60 cells that were serum starved for 
4 hours then treated with GH (growth hormone)-blocking antibodies for 6 
days (Costoya, et al, 1999).  Dylacht and co-workers (2000) also 
demonstrated that low molecular weight DNA fragmentation occurs in HL-
60 cells treated with 12 µg/ml etoposide for 3 hours.  As stated previously, 
several different techniques were used for DNA fragmentation.  It was 
decided to use Protocol 3, as all of the supernatants that could contain the 
DNA fragments were studied.  According to the source of the technique 
(www.imoax1.unimo.it.HTM), the fraction most likely to contain the lower 
molecular weight DNA fragments was the ‘T’ fraction as the small DNA 
fragments would remain in solution.  However, no fragmentation was 
present in any fraction, even though the alternative experiments prove that 
apoptosis is occurring.  The experiments were repeated many times and 
the time frames of the incubation and the concentrations of the drugs 
were varied; however the same results were obtained.  The reasons 
behind this lack of DNA fragmentation are unclear.  It is possible that the 
concentration of DNA fragments is too low for detection by ethidium 
bromide, as a low percentage of cells had undergone apoptosis.  Both 
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Dylacht and co-workers (2000) and Vermes and colleagues (1997) had 
the same difficulty with detecting DNA fragmentation, as they found that 
the apoptotic processes often occurred asynchronously.  Vermes and 
colleagues (1997) state that the DNA fragmentation technique is 
essentially qualitative and is not sensitive enough to detect spontaneous 
apoptosis, or apoptosis in small populations of cells (Vermes et al, 1997). 
Other studies have shown that there is a preliminary step in DNA 
laddering, where the DNA is digested into multiples of 300 and 50 kilo 
bases which represent higher order chromatin structure.  In some cases 
no further DNA fragmentation occurs, indicating that the endonucleases 
responsible for the continuation of the DNA cleavage are not uniform and 
that the production of DNA fragments is not a necessary step for 
apoptosis (Story & Kodym, 1998).  It is possible that this was the case in 
the current study, as the morphological studies (confocal microscopy and 
flow cytometry) did show that apoptosis was occurring.      
 
To elucidate the pathway by which the PI3-kinase pathway protects HL-60 
cells from cytotoxic drug induced apoptosis, the activation of the 
downstream targets was assessed.  The first step taken was to determine 
whether stimulation of the PI3-kinase pathway with PDGF resulted in cell 
proliferation and whether the addition of LY294002 caused a decrease in 
this growth.  The proliferation assay revealed that optimum cell growth 
appeared to be at 10 ng/ml PDGF however a decrease in cell growth did 
occur at concentrations higher than 30 ng/ml PDGF.  The reason for this 
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is unknown, but it is thought that a high concentration of PDGF may have 
a toxic effect on HL-60 cells.  However, the preliminary Trypan Blue 
exclusion studies showed a marked increase in HL-60 cell proliferation 
when treated with 50 ng/ml PDGF.  Another more probable explanation is 
that the cells grow at a higher rate and reach confluence after a short time 
frame.  The over-confluence results in a decrease in proliferation and 
increase in cell death.  Increased cell growth induced by PDGF was 
therefore not clearly demonstrated by the growth assay however, inhibition 
of the PI3-kinase pathway with 25 µM LY294002 decreased the mean 
percentage growth of the HL-60 cell population.  Thus the PI3-kinase 
pathway may play a role in PDGF mediated growth as shown when Akt 
phosphorylation was studied as described below. 
   
The PI3-kinase pathway has been reported to protect cells from apoptosis 
inducing drugs in many cell lines, as well as in HL-60 cells (O’Gorman et 
al, 2000; Brazil & Hemmings, 2001; Vivanco & Sawyers, 2002).  It has 
also been reported that stimulation of PI3-kinase results in the 
phosphorylation of Akt, and that the treatment of HL-60 cells with 
LY294002 decreased the amount of Akt phosphorylation (O’Gorman et al, 
2000).  These findings were confirmed by this study as HL-60 cells treated 
with PDGF for 15 and 30 min had a higher proportion of phosphorylated 
Akt to those treated with LY294002 prior to the addition of PDGF.  
Unexpectedly, phosphorylated Akt levels in LY294002 and PDGF treated 
cells were higher than that of the cells grown under normal conditions.  
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This leads us to believe that Akt is also phosphorylated via another 
pathway, or that LY294002 does not inhibit the PI3-kinase pathway 
entirely.  At the initiation of this study LY294002 was the most specific 
PI3-kinase pathway inhibitor available, but as mention previously (Chapter 
2.3) other more specific inhibitors are currently being tested and becoming 
commercially available.  Contradictory to the results obtained in this study, 
O’Gorman and colleagues reported that a small proportion of Total Akt is 
phosphorylated in HL-60 cells grown under normal conditions, a finding 
confirmed by several groups in other cell lines.  The majority of the studies 
conducted in the literature insert a vector containing Akt into the cell lines 
(Franke et al, 1995; Chen et al, 1999; Ramaswamy et al, 1999; Ma et al, 
2001).  The advantage of performing this transfection is that there is 
higher expression of the protein and the phosphorylation is easier to 
detect, a problem experienced in the present study.  The disadvantage is 
that the protein constitutively expressed with little or no control, and the 
results obtained are therefore not completely indicative of the processes 
occurring in vivo.  It was decided not to perform the transfection in this 
study for that reason.   
  
As previously stated in this report the PI3-kinase/Akt pathway has many 
downstream targets that are potentially responsible for protecting 
carcinogenic cells from cytotoxic drugs.  A recent study has shown that 
the PI3-kinase pathway plays a role in the activation of NF-κB DNA-
binding activity in AML (Birkenkamp et al, 2004).  Delhause and co-
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workers (2000) reported that this activation of NF-κB is due to the 
interaction of Akt with the IKK/IκB pathway.  This however was not shown 
in this study as treatment of the HL-60 cells with LY294002 did not 
decrease the levels of phosphorylation of IKK or IκB.  The exact opposite 
occurred as the phosphorylation of both IKK and IκB increased slightly 
when the HL-60 cells were incubated with LY294002.  This confirms the 
observations of Birkenkamp and colleagues (2004), who found that the 
classical NIK/IKK/IκB pathway can be activated by external factors and 
other pathways (e.g. Ras), besides the PI3-kinase/Akt pathway.  
Romashkova and Makarov (1999) reported that under certain 
circumstances PI3-kinase can activate NF-κB in an IκB independent 
manner.  It has also been shown that Akt can activate NF-κB 
transcriptional activity via an alternative IκB-independent pathway by 
modulating the transcriptional potential of RelA (Romashkova & Makarov, 
1999).  Due to time constraints on this study, the direct interaction 
between Akt and NF-κB could not be analysed.     
 
Okano and co-workers (2000) performed a study on the expression of the 
three isoforms of Akt in different cell lines.  They revealed that of the three 
isoforms, only Akt3 is differentially expressed.  In this study the semi-
quantitative method of multiplex RT-PCR was used to observe the 
expression of Akt1 mRNA in HL-60 cells treated with PDGF, LY294002, 
etoposide and cyclohexamide.  Treatment of the HL-60 cells with 50 ng/ml 
PDGF did not show a significant difference in Akt1 mRNA expression to 
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the untreated cells.  However, a decrease in expression was evident when 
the cells were treated with 25 µM LY294002, indicating that inhibition of 
the PI3-kinase pathway decreases transcription of Akt1 mRNA.  RNA 
extracted from HL-60 cells treated with 60 µg/ml etoposide was of poor 
quality, and the resultant RT-PCR bands were also not of good quality.  
The study did reveal that when the cells were treated with etoposide that 
little transcription of Akt1 mRNA occurred.  Once again, a decrease in 
expression of Akt1 mRNA was evident in the cells treated with 60 µg/ml 
etoposide and 25 µM LY294002.  Thus the PI3-kinase pathway itself may 
play a role in regulating the transcription of pro-survival genes, including 
Akt. 
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CHAPTER 5 
 
CONCLUSION 
 
Further study on this project is continuing, as Akt phosphorylation and 
mRNA expression is being monitored in the blood samples of leukaemic 
patients.  Due to time constraints on the study, the relationship between 
Akt and NF-κB was not determined.  These along with the interactions of 
other protein cascades such as MAPK with Akt are planned for the future.  
The diversity of Akt downstream targets outlined by Steelman and co-
workers (2004) also leaves many possibilities for future study.  
 
In conclusion, we confirmed that PI3-kinase stimulates phosphorylation of 
Akt, but that a minor relationship exists between Akt, IκB and IKK.  The 
expression of Akt mRNA was also shown to be affected by inhibition of the 
PI3-kinase pathway and etoposide.  This study also confirmed that 
etoposide causes apoptosis in HL-60 cells, and that there is an increase in 
apoptosis when the PI3-kinase pathway is inhibited.  This allows us to 
conclude that inhibition of the PI3-kinase pathway may sensitise 
leukaemic cells to cytotoxic-drug induced apoptosis, a finding that may be 
of therapeutic importance in the future.   
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APPENDIX 1 
 
REAGENT AND EQUIPMENT SUPPLIERS 
 
A1.1 HL-60 CELL CULTURE 
 
Incubator    Heraeus, USA 
Ethanol    ACE, RSA 
Copper Sulphate (CuSO4)  SAARCHEM, Muldersdrift, RSA 
HL-60 Cell Line   ATCC, Maryland, USA 
Sterile Culture Flasks  Nunc, Roskilde, Denmark 
RPMI-1640    Highveld Biological, Lyndhurst,RSA 
NaHCO3 Analyzed Analytical Reagent,                                            
Vorna Valley, RSA 
Penicillin Sigma-Aldrich, St Louis, MO, USA 
Streptomycin Sigma-Aldrich, St Louis, MO, USA 
Fungizone  Sigma-Aldrich, St Louis, MO, USA 
Foetal Calf Serum   Delta, Kempton Park, RSA 
Glutamine    Fluka, Sigma-Aldrich, USA 
Light Microscope   Zeiss, West Germany 
Trypan Blue     Merck, Darmstadt, Germany 
Desk Top Centrifuge  Beckmann 
Glycerol    AAR, Vorna Valley, RSA 
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Sterile cryotubes   Nunc, Roskilde, Denmark 
Sterile 50 ml Nunc tubes  Nunc, Roskilde, Denmark 
Sterile Petri Dishes   Nunc, Roskilde, Denmark 
NaCl     SAARCHEM, Muldersdrift, RSA 
KCl     SAARCHEM, Muldersdrift, RSA 
Na2HPO4    SAARCHEM, Muldersdrift, RSA 
KH2PO4    BDH Lab Reagents, England  
Filtration Unit    Millipore Corporation, USA 
22 µm filter    Whatmann, RSA 
Thick paper prefilter   Whatmann, RSA 
Pump     Millipore Corporation, USA 
 
 
A1.2 STIMULATION OF CELLS 
 
PDGF Sigma-Aldrich, St Louis, MO, USA 
HCl SAARCHEM, Muldersdrift, RSA 
Bovine Serum Albumin Highveld Biological, Lyndhurst, RSA 
Cyclohexamide Sigma-Aldrich, St Louis, MO, USA 
Etoposide Sigma-Aldrich, St Louis, MO, USA 
DMSO SAARCHEM, Muldersdrift, RSA   
LY294002 Sigma-Aldrich, St Louis, MO, USA 
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A1.3 GROWTH/CYTOTOXICTY ASSAY 
 
Growth/cytotoxicity assay kit Promega, Madison, WI, USA 
96 well sterile plates  Nunc, Roskilde, Denmark 
Multichannel pipette  Socarex, England 
96 well plate reader   Thermo Star, ADP, RSA 
 
 
A1.4 PROTEIN EXTRACTION 
 
Tris Base    Roche Laboratories, JHB, RSA   
Sucrose    SAARCHEM, Muldersdrift, RSA 
Triton X-100    Lab Reagents, RSA 
PMSF     Sigma-Aldrich, ST Louis, MO, USA 
Sodium dodecyl sulphate (SDS) ICN Biomedicals Inc, Ohio, USA 
β-Mercaptoethanol   Merck, Darmstadt, Germany 
NaCl     SAARCHEM, Muldersdrift, RSA 
Na3VO3    Sigma-Aldrich, ST Louis, MO, USA  
NaF     Sigma-Aldrich, ST Louis, MO, USA 
Sodium pyrophosphate  Sigma-Aldrich, ST Louis, MO, USA 
EDTA     BDH Lab Reagents, England 
Microcentrifuge tube  Eppendorff, USA 
Bench top microcentrifuge  Eppendorff, USA 
Bromophenol Blue   Merck, Darmstadt, Germany 
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A1.5 TOTAL PROTEIN DETERMINATION 
 
Sodium Potassium Tartrate SAARCHEM, Muldersdrift, RSA 
CuSO4    SAARCHEM, Muldersdrift, RSA 
NaOH     SAARCHEM, Muldersdrift, RSA 
Sodium Carbonate   SAARCHEM, Muldersdrift, RSA 
Folinciocalteau   Merck, Darmstadt, Germany 
Spectrophotometer   DU-65 Spectrophotometer 
     Soft Pac Module Quant II linear 
 
 
A1.6 ELECTROPHORESIS 
 
Mini Gel system   Hoefer, USA 
Acrylamide    BDH, Lab Suppliers, England  
Bisacrylamide   Merck, Darmstadt, Germany 
Ammonium Persulphate (APS) BDH, Lab Suppliers, England 
TEMED    Merck, Darmstadt, Germany 
Isopropanol    AAR, JHB, RSA 
Molecular Weight Markers  Amersham Pharmacia Biotech, RSA 
Electrophoresis apparatus  Hoefer Scientific Instruments 
Cooling system   Hoefer Scientific Instruments 
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Power Pack    Hoefer Scientific Instruments 
Coomassie Brilliant Blue R-250 Merck, Darmstadt, Germany 
Acetic acid    AAR, JHB, RSA 
Methanol    AAR, JHB, RSA 
 
 
A1.7 WESTERN BLOTTING 
 
Nitrocellulose Paper  Osmonics, JHB 
Glycine    Merck, Darmstadt, Germany 
Western blotting aparatus  Transfer Electrophoresis Unit TE Series 
Amido Black    Merck, Darmstadt, Germany 
 
 
A1.8 IMMUNOBLOTTING 
 
Total Akt Antibody   Cell Signalling, Biolabs, USA 
Phospho-Akt Antibody  Cell Signalling, Biolabs, USA 
Phospho-IκB Antibody  Cell Signalling, Biolabs, USA 
IKK Antibody    Cell Signalling, Biolabs, USA 
Tween-20    Merck, Darmstadt, Germany  
Donkey-anti-rabbit 2° Antibody Amersham Life Science, UK 
Sheep-anti-mouse 2° Antibody Amersham Life Science, UK 
Non-fat-dry milk powder  Elite, JHB, RSA 
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Advanced ECL kit   Amersham Life Science, UK 
Cling Film    Glad, RSA 
X-ray Film    Fuji, UK 
 
 
A1.9 CONFOCAL MICROSCOPY 
 
Acridine Orange   Merck, Darmstadt, Germany 
Confocal Microscope  Zeiss, West Germany 
 
 
A1.10 FLOW CYTOMETRY 
 
Flow cytometry tubes  Beckmann-Coultier, Germany 
YO-PRO-1    Molecular Probes Inc, Netherlands 
Propridium Iodide   Fluka, Sigma-Aldrich, USA 
Flow Cytometer   Beckmann-Coultier, Germany 
 
 
 
A1.11 DNA EXTRACTION 
 
RNase-A    Boehringer Mannheim, West Germany 
NP-40     Boehringer Mannheim, West Germany 
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Proteinase K    Roche Laboratories, JHB, RSA 
Sodium Acetate   Merck, Darmstadt, Germany 
Vortex apparatus   Chilt Scientific, USA 
Agarose    Tech Com Ltd, Hong Kong 
Ethidium Bromide   Sigma-Aldrich, ST Louis, MO, USA 
Gel Chamber   Hoefer, USA 
DNA viewing apparatus  Syngene gel viewing system, USA 
 
 
A1.12 LDH ASSAY 
 
Triethanolamine   SAARCHEM, Muldersdrift, RSA 
Monosodium Pyruvate  SAARCHEM, Muldersdrift, RSA 
NADH     Sigma-Aldrich, ST Louis, MO, USA 
 
Spectrophotometer   Perkin-Elmer spectrophotometer with 
a chart recorder 
 
 
A1.13 RNA EXTRACTION 
 
Diethyl Pyrocarbonate  SAARCHEM, Muldersdrift, RSA 
Tri-Reagent   Sigma-Aldrich, St Louis, MO, USA 
Chloroform    AAR, Vorna Valley, RSA 
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A1.13.1   VISUALISATION OF RNA 
 
MOPS    Merck, Darmstadt, Germany   
Formamide    SAARCHEM, Muldersdrift, RSA  
RNase Free water   Sabax, RSA 
 
 
A1.14 REVERSE TRANSCRIPTION-POLYMERASE 
CHAIN REACTION ANALYSIS OF AKT1 MRNA 
 
cDNA synthesis kit   Promega, Madison, WI, USA 
PCR Machine   Hybaid Touchdown Thermocycler 
AKT1 primers   Whitehead Scientific, Cape Town, RSA 
GAP-DH primers   Whitehead Scientific, Cape Town, RSA 
PCR kit    Roche Laboratories, JHB, RSA 
 
 
A1.15 ENDONUCLEASE RESTRICTION OF AKT1 PCR  
PRODUCT 
 
XhoI     Promega, Madison, WI, USA 
AvaI     Promega, Madison, WI, USA 
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HaeIII     Promega, Madison, WI, USA 
Buffer M    Promega, Madison, WI, USA 
Buffer H    Promega, Madison, WI, USA 
Buffer B    Promega, Madison, WI, USA 
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APPENDIX 2 
 
SOLUTIONS AND TECHNIQUES 
 
 
A2.1 CELL CULTURE 
 
A2.1.1 FUMIGATION OF CULTURE ROOM 
 
A2.1.1.1 Fumigation solution 
 
 2 g Potassium Permanganate 
 20 ml Formaldehyde 
 
A2.1.1.2 Methodology 
 
• Clean Incubator and remove CuSO4 solution from the tray 
• Prepare fumigation solution 
• Place one beaker with solution in the switched off open incubator  
• Place second beaker with solution in the switched on Laminar Flow 
hood 
• Leave the room immediately, close door and leave for two days 
• Potassium permanganate will release formalin and fumigate the area  
• Remove beakers, dispose of solutions into a formalin waste container 
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• Put freshly prepared CuSO4 solution into the tray in the incubator 
• Switch on incubator  
 
A2.1.2 STERILIZATION SOLUTIONS 
 
A2.1.2.1 70% Ethanol 
  
 700 ml Ethanol 
 300 ml Distilled water 
 
A2.1.2.2 Adcodyne 
  
 4 ml Adcodyne 
 996 ml Distilled Water 
 
A2.1.1.3 10% CuSO4 
 
 10 g CuSO4 
 100 ml Distilled water 
 
 
 
 135 
A2.1.3 THE RPMI-1640 MEDIUM 
 
Prior to preparing medium, all objects to be used must be autoclaved 
using the water cycle.  This includes the medium bottles and filtering unit. 
 
Table A2.1 Recipe for RPMI-1640  
 
Materials 1 Litre 5 Litres 
RPMI-1640 10.41g 52.05g 
NaHCOµ 2.00g 10.00g 
Penicillin 0.26g 1.30g 
Streptomycin 0.43g 2.15g 
  
 
The above is made up in 800ml or 4.5l Baxter water and gently stirred 
using a magnetic stirrer.  Make up to the final volume in a volumetric flask, 
then transfer back into a conical flask for easier filtration. 
 
A2.1.4 FILTRATION 
• On the tripod part of the filtering unit place: 
I. Round metal grid with the bars down 
II. Metal filter with rough side up 
III. 22µm filter – hold the edge with forceps, allowing the opposite edge 
to touch the metal filter and let it fall gently 
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IV. Thick paper prefilter with rough side up – wet with distilled water 
V. Position top of unit so that the screw holes line up, put screws in 
loosely 
• Wrap foil around the top of the glass bell and upper two nozzles – the 
central one with the lever up (open) 
• Autoclave using the liquid cycle, with the schott bottles 
• Remove the cotton filter from a sterile 10ml disposable pipette and 
attach to pump inlet tube.  Place in Baxter water.  Attach the shorter 
tube to the filtering unit.  Swab glass bell and waste bottle with alcohol, 
flame and pump water through into the waste bottle 
• Tighten nuts on the filtering unit using the key 
• Pump water by switching from the central position on the pump to the 
right, speed < 1.0 (±0.8) 
• Switch on the pump, when the water reaches the filter unit move the 
upright lever to the horizontal position 
• Transfer pipette into unfiltered medium, allow some medium to pass 
through the filter into the waste bottle before filling the schott bottles to 
900ml 
• Store medium at 4°C until required 
 
 
A2.1.5 ADDITIONS TO THE MEDIUM 
 
A2.1.5.1 Foetal Calf Serum (FCS)  
Heat inactivate the FCS at 56°C for 20 minutes 
Add 100 ml inactive FCS to 900 ml RPMI-1640 = 10% FCS 
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A2.1.5.2 Fungizone 
Add 200 µl fungizone to 1 L of 10% FCS in RMPI-1640 
 
A2.1.5.3 Glutamine 
 3g tissue culture grade glutamine 
100ml Baxter water 
Makes up a 100X concentration, store in 10ml vials at -20°C 
Glutamine has a 3-week half-life, if the medium has been stored for 
longer than 3 weeks then add 10ml to 1 L of medium 
 
A2.1.6 CELL COUNTING 
 
A2.1.6.1 2% Trypan Blue Stain 
Solution 1: 0.2% w/v trypan blue 
     0.2g Trypan blue in 100 ml sterile water 
 Solution 2: 52 Saline 
   1.06g NaCl in 25 ml sterile water 
 Mix 4 parts solution 1 to 1 part solution 2 
 Store at RT 
 
A2.1.7 PHOSPHATE BUFFERED SALINE (PBS) 
  
0.9% NaCl      9 g 
 2.8 mM KCl      0.2 g 
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 8.5 mM Na2HPO4     1.20 g 
 1.5 mM KH2PO4     0.2 g 
 
 
A2.2 STIMULATION OF CELLS 
 
A2.2.1 PLATELET DERVIVED GROWTH FACTOR 
 
10 µg of PDGF was resuspended in 1 ml 4 mM HCl containing 0.1% BSA, 
aliquoted out and stored at -20°C until required.  This gave a stock 
solution of 10 ng/µl.  For experimental conditions cells were treated with 
50 ng/ml PDGF that is equivalent to 5 µl in 1 ml of medium. 
 
A2.2.1.1 4 mM HCl + 0.1% BSA 
 
3.82 µl HCl 
9.996 ml Sterile water 
1 g BSA 
 
A2.2.2 ETOPOSIDE 
 
25 mg of etoposide was resuspended in 833 µl DMSO to give a stock 
solution of 30 mg/ml.  The recommended concentration for experimental 
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conditions was 60 µg/ml that was equivalent to 2 µl of etoposide stock in 1 
ml of medium. 
 
A2.2.3 CYCLOHEXAMIDE 
 
A stock solution of cyclohexamide (3 mg/ml) was prepared by dissolving 3 
mg of cyclohexamide in 1 ml DMSO.  Cyclohexamide was used as an 
apoptotic positive control at a concentration of 3 µg/ml (1 µl in 1 ml).   
 
A2.2.4 LY294002 
 
A stock solution (25 mM LY294002) was prepared by resuspending the 
obtained 5 mg LY294002 in 650 µl DMSO.  This was aliquoted out and 
stored at -20°C.  The PI3-kinase pathway was inhibited by incubating cells 
with 25 µM LY294002 (1 µl in 1 ml) for 1 hour prior to incubation with other 
stimulants.  
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A2.3 GROWTH/CYTOTOXICITY ASSAY 
 
A2.3.1 PREPARATION OF PLATES 
 
A2.3.1.1 PDGF 
 
To give the correct final concentrations of PDGF the different 
concentrations were prepared as a 4X solution.  25µl of the corresponding 
concentration was added to the respective well.  A 1 in 10 dilution of stock 
PDGF (10 ng/µl) was prepared to give a master solution with a 
concentration of 1 ng/µl  
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Table A2.2 Preparation of the five different concentrations of PDGF  
 
Final PDGF 
Concentration 
4X Concentration 
µl of 1 ng/µl PDGF 
Added 
µl Medium Added 
10 ng/ml 40 1 24 
30 ng/ml 120 3 22 
50 ng/ml 200 5 20 
70 ng/ml 280 7 18 
90 ng/ml 360 9 16 
  
 
A2.3.1.2 LY294002 
 
To give the correct final concentration of LY294002, the stock solution 
was prepared as a 4X solution.  The samples to be treated with LY294002 
had 25µl of the stock solution added to its well. 
 
Final concentration of LY294002  = 25 µM 
4X concentration   = 100 µM 
µl LY294002 added   = 4 µl 
µl Medium added   = 996 µl 
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A2.3.1.3 Etoposide 
 
A 4X stock solution of the different concentrations of etoposide were 
prepared in order to obtain the correct final concentrations. 25µl of the 
corresponding concentration was added to the respective well. A 1 in 10 
dilution of stock etoposide (30 mg/ml) was prepared to give a master 
solution with a concentration of 3 mg/ml 
  
Table A2.3 Preparation of the five different concentrations of Etoposide  
 
Final etoposide 
Concentration 
4X Concentration 
µl (3 mg/ml) etoposide 
Added 
µl Medium Added 
20 µg/ml 80 0.6 24.4 
40 µg/ml 160 1.3 23.7 
60 µg/ml 240 2 23 
80 µg/ml 320 2.7 22.3 
100 µg/ml 400 3.3 21.7 
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A2.4 PROTEIN EXTRACTION 
 
A2.4.1 LYSING BUFFER A 
  
20 mM Tris-HCl (pH 7.5)    0.24 g 
 Sucrose      8.55 g 
 1% Triton-X 100     1 ml 
 Dissolve in 80 ml distilled water 
 Adjust pH with HCl 
 Make up to 100 ml 
 Store in a dark bottle 
 
A2.4.2 LYSING BUFFER B 
  
20 mM Tris-HCl (pH 7.5)    0.24 g 
 Sucrose      8.55 g 
 1% Triton-X 100     1 ml 
Dissolve in 80 ml distilled water 
 Adjust pH with HCl 
 Make up to 99 ml 
 Store in a dark bottle 
 Prior to lysing cells, add 1 µl 100 mM PMSF per 99 µl lysis buffer 
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A2.4.3 LYSING BUFFER C (SDS-LYSIS BUFFER) 
  
62 mM Tris-HCl (pH6.8)    0.75 g 
 2% SDS      2 g 
 10% glycerol      10 g 
 0.5% β-mercaptoethanol    0.5 ml 
 Dissolve in 80 ml distilled water 
 Adjust pH with HCl 
 Make up to 100 ml 
 Store in a dark bottle 
  
A2.4.4 LYSING BUFFER D  
  
20 mM Tris-HCl (pH 7.5)    0.24 g 
 100 mM NaCl     0.58 g 
 1% Triton-X 100     1 ml 
 0.1% SDS      0.1 g 
 Dissolve in 80 ml distilled water 
 Adjust pH with HCl 
 Make up to 93 ml 
 Store in a dark bottle  
Prior to lysis add the following to 93 µl lysis buffer: 
1 µl 100mM Na3VO3  
1 µl 100 mM PMSF  
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5 µl 100 mM NaF 
 
A2.4.5 LYSING BUFFER E (AKT LYSING BUFFER) 
  
20 mM Tris-HCl (pH 7.2)    0.24 g 
 150 mM NaCl     0.876 g 
 10% glycerol      10 ml 
 1% Triton-X      1 ml 
 30 mM Sodium Pyrophosphate   0.797 g 
 1 mM EDTA      0.037 g 
 Aliquot into 10 ml tubes and store at -20°C until required 
Prior to lysing cells, add the following to 97 µl lysis buffer: 
1 µl 100mM Na3VO3  
1 µl 100 mM PMSF  
1 µl 1 M NaF 
 
A2.4.6 ADDITIONS TO LYSING BUFFERS 
 
A2.4.6.1 PMSF (100 mM Stock) 
  
0.17 g PMSF 
Dissolve in 10 ml isopropanol to reduce degradation in aqueous 
water 
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 Aliquot in to eppendorff tubes and store at -20°C until required 
 
A2.4.6.2 Sodium Vanadate (100 mM Stock) 
  
2.5 g Sodium Vanadate 
 Dissolve in 8 ml distilled water 
 Adjust pH to 10 
 Boil until translucent 
 Readjust pH to 10 
 Store in aliquots frozen at -20°C 
 
A2.4.6.3 NaF (1 M Stock) 
 
0.42 g NaF 
 Dissolve in 10 ml distilled water 
 Store at -20°C in aliquots 
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A2.5 TOTAL PROTEIN DETERMINATION 
 
A2.5.1 STOCK SOLUTIONS 
 
A2.5.1.1 0.1% BSA 
 
 0.1g BSA 
 100ml distilled water 
 Aliquoted and stored at -10°C 
 
A2.5.1.2 0.1M Sodium Hydroxide 
 
 4g NaOH 
 1 litre distilled water 
 Store at RT 
 
A2.5.1.3 2% Sodium Carbonate in 0.1M NaOH 
 
 10g Sodium carbonate 
 500ml 0.1M NaOH 
 Store at RT 
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A2.5.1.4 2% w/v Sodium Potassium Tartrate 
 
 1g sodium potassium tartrate 
 50ml sterile water 
 Store at RT 
 
A2.5.1.5 1% w/v Copper Sulphate 
 
 0.5g CuSO4 
 50ml sterile water 
 Store at RT 
 
A2.5.2 WORKING REAGENT A 
 
Prepare freshly by adding the following components in strict order with 
constant stirring: 
 1ml 2% w/v sodium potassium tartrate 
 1ml 1% w/v copper sulphate 
 100ml 2% sodium carbonate in 0.1M NaOH 
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A2.5.3 THE PROTEIN STANDARD CURVE 
 
Table A2.4 The protein standard curve that was prepared in duplicate 
 
Sample  
Number 
 
Protein Concentration 
 
1% BSA (µl) Water (µl) 
1 0 0 1000 
2 25 25 975 
3 50 50 950 
4 75 75 925 
5 100 100 900 
6 150 150 850 
Sample X 10 µl of sample 990 
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A2.6 SDS-PAGE ELECTROPHORESIS 
 
A2.6.1 RUNNING GEL SOLUTIONS 
 
A2.6.1.1 Stock Acrylamide (RGA) (30%) 
 
30% Acrylamide      15 g   
0.8% Bisacrylamide      0.4 g  
Make up to 50 ml with distilled water 
   Store in a dark bottle in the fridge 
  
A2.6.1.2 Running Gel buffer (RGB) (pH 8.8)  
 
1.5 M Tris HCl      9.085 g 
 0.4% SDS       0.2 g   
Make up to 50 ml with distilled water 
Correct pH with HCl and store in the fridge 
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A2.6.2 STACKING GEL SOLUTIONS 
 
A2.6.2.1 Stacking Gel Acrylamide (SGA) (16%) 
 
16% Acrylamide      8 g   
0.512% Bisacrylamide     0.256 g  
Make up to 50 ml with distilled water 
Store in a dark bottle 
 
A2.6.2.2 Stacking Gel Buffer (SGB) (pH 6.8) 
 
 0.5 M Tris       3.0285 g  
 0.4% SDS       0.2 g   
 Make up to 50 ml with distilled water 
 Correct pH with HCl (pH drops rapidly after a certain point) 
 Store in the fridge 
 
A2.6.3 PREPARATION OF SDS-PAGE 
 
• Wash the casting chamber well, rinse with distilled water 
• Wipe plates down with alcohol and allow to dry 
• Assemble casting chamber 
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Table A2.5 Three different concentrations of Running Gels 
 
Reagent 10% 12.5% 15% 
Distilled Water 5 ml 4 ml 3 ml 
RGB 3 ml 3 ml 3 ml 
RGA (30%) 4 ml 5ml 6 ml 
 
 
• A 12.5% gel was generally prepared 
• Mix the solutions well and degas for 10 minutes 
• Make up fresh 0.1 g/ml ammonium persulphate in distilled water  
• Add 0.25 µg/ml TEMED (3 µl per gel) 
• Add 0.5 µg/ml APS  (60 µl per gel) 
• Gently swirl to mix 
• Pour into casting chamber, allow to set for 15-20 minutes 
• Overlay with isopropanol to ensure a flat surface and to exclude air 
• Once the gels have set pour off the isopropanol and rinse with a 1 in 4 
dilution of SGB  
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Table A2.6 The Stacking Gel 
  
Reagent 4 % 
Distilled Water 2.5 ml 
SGB 1.25 ml 
SGA (16%) 1.25 ml 
  
 
• Mix solutions well and degas for 10 minutes 
• Add 0.25 µg/ml TEMED  (1.5 µl per gel) 
• Add 0.5 µg/ml APS  (25 µl per gel) 
• Pour off 1 in 4 dilution of SGB 
• Pour over running gel  
• Insert combs and allow to set overnight 
 
 
A2.6.4 ELECTROPHORESIS 
 
A2.6.4.1 Running Buffer (pH 8.3) 
 
 0.025 M Tris       3.0285 g  
 0.192 M glycine      14.4 g  
 0.1% SDS       1 g  
 Make up to 1 L with milli-Q water 
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Check pH, if not correct, throw solution away and remake.  
DON’T correct pH with HCl 
Store in the fridge 
 
A2.6.4.2 Loading Buffer (pH 6.8) 
 
62 mM Tris-HCl (pH6.8)    0.75 g 
 2% SDS      2 g 
 10% glycerol      10 g 
 0.5% β-mercaptoethanol    0.5 ml 
 Dissolve in 80 ml distilled water 
 Adjust pH with HCl 
 Make up to 100 ml 
 Store in a dark bottle 
 
A2.6.5 STAINING GELS  
 
A2.6.5.1 Coomassie Blue Stain (0.1%) 
 
 H2O : Acetic Acid : Methanol 
 17 :          1.5 :       20 
 34ml :          3 ml :      40 ml 
 Add a few grains of Coomassie blue 
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Gels are removed from the plates, washed with tap water and then placed 
in stain overnight.   
 
A2.6.5.2 Coomassie Blue Destain 
 
 H2O : Acetic Acid : Methanol 
 17 :          1.5 :       20 
 34ml :         3 ml :      40 ml 
 Can be recycled by filtering through active charcoal 
The stain is poured off the gels, and the destain added.  This is left to 
destain until the blue protein bands are visible on a clear background.  
 
  
A2.7 WESTERN BLOTTING  
 
A2.7.1 TRANSFER BUFFER (PH 8.5) 
 
 25 mM Tris       6.055 g  
 0.2 M Glycine      30.028 g  
 20% Methanol      400 ml  
 Make up to 2 L 
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A2.7.2 STAINING A WESTERN BLOT 
 
A2.7.2.1 Amido Black Stain 
 
0.1% Amido Black Stain     0.1 g  
10% Methanol      10 ml  
2% Acetic Acid      10 ml  
88 ml Water     
The blots were removed from the cassettes, washed with tap water 
and then placed in stain overnight.   
 
  
 
A2.7.2.2 Amido Black Destain 
 
50% Methanol      50 ml   
7% Acetic Acid      7 ml   
43 ml Water     
Can be recycled by filtering through active charcoal 
The stain is poured off the blots, and the destain added.  This is left 
to destain until the blue protein bands are visible on a white 
background. 
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A2.8 IMMUNOBLOTTING 
 
A2.8.1 SOLUTIONS 
 
A2.8.1.1 10X Tris buffered saline (TBS) (pH 7.6) 
 
 24.2g Tris 
 80g NaCl 
 Adjust pH with HCl and make up to 1 L with distilled water 
 Make a 1 in 10 dilution for 1X TBS 
 
A2.8.1.2 Wash Buffer (TBS-T) 
 
 999 ml 1X TBS 
0.1% Tween-20      1 ml  
 
A2.8.1.3 BSA Blocking Buffer & 1° Antibody dilution buffer 
 
 1X TBS-T       3 ml   
 5% Bovine serum albumin (BSA)    0.15 g   
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A2.8.1.4 Milk powder Blocking Buffer & 2° Antibody dilution 
buffer 
 
 1X TBS-T       25 ml   
 5% w/v non-fat dry milk     1 g   
 
A2.8.2 STRIPPING AND REPROBING MEMBRANES 
 
A2.8.2.1 Stripping Buffer (100ml) 
 
 2% SDS       2 g   
 62.5 mM Tris-HCl (pH 6.7)     0.757g 
Prior to use add 100 mM β-mercaptoethanol (140 µl in 20 ml 
stripping buffer)  
 
A2.8.2.2 Methodology 
 
• Submerge membrane in stripping buffer and incubate at 50°C for 30 
min with occasional agitation 
• Wash membrane in 1X TBS twice for 10min each 
• Block and immunoblot as usual 
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A2.8.3 DEVELOPMENT OF THE X-RAY FILM 
 
A2.8.3.1 Developer 
 
200 ml Solution 1 
2.2 ml Solution 2 
Make a 1 in 5 dilution with distilled water 
Store in a dark bottle and replace every month 
 
A2.8.3.2 Fixer 
 
Make a 1 in 5 dilution with distilled water 
 
A2.8.3.3 Method 
 
• Place exposed X-ray in developer until bands start to appear 
• Wash X-ray in water bath 
• Place X-ray in fixer until the background appears clear 
• Wash X-ray in water bath 
• Allow X-ray to dry 
 
 
 
 160 
A2.9 CONFOCAL MICROSCOPY 
 
A2.9.1  ACRIDINE ORANGE-ETHIDIUM BROMIDE STAIN 
 
 100 mg Acridine Orange 
 100 mg Ethidium Bromide 
 1 ml PBS 
 Mix well and store at 4°C 
 
A2.10 FLOW CYTOMETRY 
 
A2.10.1   PROPIDIUM IODIDE 
 1 mg Propidium Iodide 
 100 µl DMSO 
 Mix well and store at -20°C 
A2.11 DNA EXTRACTION 
 
A2.11.1 RNASE A 
 
Dissolve 10 mg RNase A in 1 ml TE buffer 
Heat for 10 min at 70°C 
Cool slowly 
Aliquot and store at -20°C 
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A2.11.2 PROTEINASE K (10 MG/ML) 
 
10 mg Proteinase K 
4 µl 0.5 M EDTA 
100 µl 10% SDS 
Make up to 1 ml with distilled water 
 
A2.11.3 TE BUFFER PH 7.6 
 
12.1 g Tris 
2 ml 0.5 M EDTA 
Dissolve in 90 ml distilled water 
Adjust pH with HCl 
Make up to 100 ml 
 
A2.11.4 10% SDS 
 
0.1 g SDS 
Dissolve in 10 ml distilled water 
 
A2.11.5 0.5 M EDTA (PH 7.5) 
 
18.61 g NaEDTA 
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Dissolve in 80 ml distilled water 
Adjust pH with HCl 
Make up to 100 ml   
 
A2.11.6 1 M EDTA (PH 7.5) 
 
37.2 g EDTA 
Dissolve in 80 ml distilled water 
Adjust pH with HCl 
Make up to 100 ml 
 
A2.11.7 1 M TRIS HCL (PH 7.4) 
 
12.1 g Tris 
Dissolve in 80 ml distilled water 
Adjust pH with HCl 
Make up to 100 ml 
 
A2.11.8 GEL LOADING BUFFER 
 
40mM Tris 
20mM sodium acetate.3H2O 
1mM EDTA-Na2.2H2O 
50% glycerol 
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pH to 7.2 with acetic acid 
 
A2.11.9 3 M SODIUM ACETATE 
 
3.657 g Sodium Acetate 
Dissolve in 100 ml distilled water 
 
A2.11.10 70 % ETHANOL 
 
700 ml ethanol 
300 ml distilled water 
A2.11.11 5 M NaCl  
 
 222 g NaCl 
 100 ml distilled water 
 
A2.11.12 LYSIS BUFFER 1 
 
0.5 ml 1M Tris-HCl (pH 7.4)  
0.5ml 1M EDTA  
10 µl RNase-A                                     
2.5 µl NP-40 
 
A2.11.13 LYSIS BUFFER 2  
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0.5 ml 1M Tris-HCl (pH 7.4)  
0.5ml 1M EDTA  
10 µl RNase-A                                     
2.5 µl NP-40 
 
A2.11.14 TTE BUFFER 
 
100 ml TE buffer (pH 7.4) 
200 µl Triton-X 
Store at 4°C 
 
A2.11.15 BROMOPHENOL BLUE LOADING BUFFER 
 
50 g Sucrose 
50 mM EDTA 
0.1 g Bromophenol Blue 
10 g Ficoll 
Make up to 100 ml with distilled water 
 
A2.11.16 50X TAE BUFFER (STOCK SOLUTION) 
 
 242 g Tris  
 100 ml 0.5M EDTA (pH 8.0)      
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 57.1 ml glacial acetic acid 
 Make up to 1 L with distilled water 
 Dilute to a 1X buffer when running gels 
  
A2.11.17 1X TAE BUFFER 
  
 20 ml 50X TAE buffer 
 980 ml distilled water 
  
 
A2.11.18 ETHIDIUM BROMIDE (STOCK SOLUTION) 
 
 100mg Ethidium Bromide 
 Dissolve in 10ml distilled water 
 Store in a glass bottle wrapped in foil at 4°C 
 
A2.11.19 1% AGAROSE GEL 
  
 1 g Agarose 
 100 ml 1X TAE Buffer 
 Boil to dissolve agarose 
 Allow to cool to approximately 60°C 
Add 5 µl Ethidium Bromide 
 Pour into gel chamber 
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A2.12 LDH ASSAY 
 
A2.12.1 LDH BUFFER (PH 7.4) 
 
 50 mM Triethanolamine     665 µl 
 5 mM EDTA       0.186 g 
 100 ml distilled water 
 
A2.12.2 85 mM POTASSIUM PYRUVATE 
 
 0.019 g Potassium Pyruvate 
 2 ml LDH buffer 
 
 
A2.12.3 4.5 mM NADH 
 
 0.016 g NADH 
 5 ml LDH buffer 
 
 
 
A2.12.4 REACTION MIXTURE 
  
 100 µl 4.5 mM NADH 
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 2.6 ml LDH buffer 
 200 µl Sample 
 100 µl 87 mM Pyruvate (Added to start the reaction) 
 
 
A2.13 RNA EXTRACTION, QUANTIFICATION AND 
ANALYSIS 
 
A2.13.1 DEPC WATER 
 
 200 µl DEPC 
 1 L Baxter water 
 Shake to release gasses 
 Allow solution to stand overnight 
 Autoclave on wet cycle to destroy DEPC 
 Tighten lid and store at RT 
 Note: DEPC is toxic and should be worked with in a fume cupboard 
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A2.13.2 VISUALISATION OF ISOLATED RNA INTEGRITY 
 
A2.13.2.1 10X MOPS (pH 5.5-7.0) 
 
Add the following reagents into a sterile schott bottle: 
 20.93 g MOPS 
 2.05 g Anhydrous Sodium Acetate 
 1.86 g EDTA 
 Make up to 500 ml with sterile water 
 Measure pH 
 Add 100 µl DEPC (in the fume cupboard) 
 Autoclave on the wet cycle 
 Store at RT in a dark bottle 
Extreme care must be taken in order not to introduce RNases into 
the solution 
 
A2.13.2.2 1% Denaturing Agarose Gel 
 
 0.5 g Agarose (RNA grade) 
 42.3 ml DEPC water 
 5 ml 10X MOPS 
 Dissolve by boiling for 5 min 
  Allow to cool to approximately 60°C 
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 Add 2.7 µl Formaldehyde 
 Add 2.5 µl Ethidium Bromide 
  
A2.13.2.3 RNA Sample Buffer 
 
 360 µl Formamide 
 80 µl 10X MOPS 
 130 µl Formaldehyde 
 135 µl DEPC 
 80 µl Glycerol 
 5 µl Saturated Bromophenol Blue 
  
A2.13.2.4 Denaturing Gel Running Buffer 
 
40 ml 10X MOPS 
360 ml DEPC water 
20 µl Ethidium Bromide 
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A2.14  REVERSE TRANSCRIPTION-POLYMERASE 
CHAIN REACTION ANALYSIS OF AKT1 MRNA  
 
Table A2.7 The RT-PCR Master Mix  
 
Reagent Final Concentration Volume per Sample 
10 X Reaction Buffer  12 2 µl 
25 mM MgCl2 5 mM 4 µl 
10 mM dNTP Mix 1 mM 2 µl 
Oligo-p(dT)15 Primer 0.025 µg/µl 1 µl 
RNase Inhibitor 20 Units 0.5 µl 
Reverse Transcriptase 15 Units 0.63 µl 
Sterile Water - Variable 
RNA Sample 2 µg Variable 
Final Volume  20 µl 
 
Following cDNA synthesis, the product was made up to 100 µl with 
nuclease free water 
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A2.14.1  AKT PRIMERS 
 
The Akt forward and reverse primers were diluted to a stock concentration 
of 100 pmole/µl by adding 1 µl primer to 99 µl Sterile water.  The stock 
solution was stored at -70°C.  A working dilution of 10 pmole/µl (10 µM) 
was prepared by diluting the stock solution 1:10 with sterile water.  Small 
quantities of working dilution were prepared and stored at -20°C. 
 
A2.14.1   GAP-DH PRIMERS 
 
The GAP-DH primers were diluted to a stock concentration of 250 
pmole/µl.  This stock solution was stored at -70°C.  A working dilution of 
10 pmole/µl (10 µM) was prepared by diluting the primers 1:50 with 
nuclease free water.  The working dilution was prepared in small volumes 
and stored at -20°C. 
 
A2.14.3  THE MULTIPLEX PCR MASTER MIX 
 
The dNTP mix that was added to the PCR master mix was the difference 
between the Reverse Transcription and PCR reactions.  This was to 
ensure that the dNTP concentration remained at 0.2 mM throughout the 
RT-PCR reaction.   
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Table A2.8 The Multiplex PCR Master Mix 
 
Reagent Final Concentration Volume (µl) per Sample 
10X Reaction Buffer 12 5 µl 
MgCl2 1.5 mM 3 µl 
10 mM dNTP Mix 0.2 mM 0.5 µl 
Akt Forward Primer 0.4 µM 2 µl 
Akt Reverse Primer 0.4 µM 2 µl 
GAP-DH Forward Primer 0.05 µM 0.5 µl 
GAP-DH Reverse Primer 0.05 µM 0.5 µl 
Taq Polymerase 2.5 Units 0.5 µl 
Sterile Water - Variable 
cDNA - 10 µl 
Final Volume  50 µl 
 
 
A2.14.4 VISUALISATION OF THE PCR PRODUCT 
 
 A2.14.4.1   2% Agarose Gel 
  
 1 g Agarose 
 50 ml 12 TAE Buffer 
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 Boil to dissolve agarose 
 Allow to cool to approximately 60°C 
Add 2.5 µl Ethidium Bromide 
 Pour into gel chamber 
 
 A2.14.4.2 DNA molecular weight marker 
 
 4 µl DNA molecular weight marker 
 3 µl Bromophenol blue loading buffer 
 3 µl Distilled water 
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A2.15 ENDONUCLEASE RESTRICTION OF AKT1 PCR 
PRODUCT 
 
Table A2.9 The Restriction Enzyme Master Mix for the three Restriction 
enzymes used 
 
Reagent Buffer Volume 
PCR Product  6 µl 
Sterile Water  12µl 
Xho I M 2 µl 
Ava I H 2 µl 
Hae III B 2µl 
Final Volume  20 µl 
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